brivudine profile

brivudine: anti-herpes agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	446727
CHEMBL ID	31634
SCHEMBL ID	99350
SCHEMBL ID	141408
MeSH ID	M0073782

Synonym
AKOS015833980
nsc-633770
bromovinyldeoxyuridine
zostex
rp-101
a-176
EU-0100175
LOPAC0_000175
D07249
brivudine (inn)
zostex (tn)
brivudine
ua-618
helpin
69304-47-8
bvdu
brvdurd
nsc633770
(e)-5-(2-bromovinyl)-2'-deoxyuridine
5-[(e)-2-bromovinyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
(e)-5-(2-bromovinyl)-durd
bv-durd
brivudin
(e)-5-(2-bromovinyl)-deoxyuridine
DB03312
BVD ,
5-bromovinyldeoxyuridine
c11h13brn2o5
trans-5-(2-bromovinyl)-2'-deoxyuridine
brivudina [inn-spanish]
nsc 633770
ccris 2831
uridine, 5-(2-bromoethenyl)-2'-deoxy-, (e)-
brivudine [inn]
brivudinum [inn-latin]
uridine, 5-(2-bromovinyl)-2'-deoxy-, (e)-
NCGC00093656-01
NCGC00093656-02
B 9647
B3404
CHEMBL31634
rp101
5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
2m3055079h ,
brivudina
brivudinum
unii-2m3055079h
cas-69304-47-8
dtxsid0045755 ,
tox21_111213
dtxcid8025755
CCG-204270
zerpex
bdbm50366681
bridic
brivox
LP00175
brivudine [mi]
5-((e)-2-bromovinyl)-2'-deoxyuridine
brivudine [who-dd]
brivudine [mart.]
S5009
SCHEMBL99350
SCHEMBL141408
bromovinyldeoxyuridine; 5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
J-700153
e-5-(2-bromovinyl)-2'-deoxyuridine
ODZBBRURCPAEIQ-PIXDULNESA-N
uridine, 5-[(1e)-2-bromoethenyl]-2'-deoxy-
SR-01000075726-1
sr-01000075726
CS-6292
HY-13578
5-((e)-2-bromovinyl)-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
5-[(e)-2-bromoethenyl]-2'-deoxyuridine
ZB0745
5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
AS-35234
Q904107
SDCCGSBI-0050163.P002
EN300-7413261
BP-58637

Excerpt	Reference	Relevance
"Brivudine is an analog of thymidine, and is incorporated into the viral DNA. "	( Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Rabasseda, X, 2003)	3.2

Excerpt	Reference	Relevance
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."	( Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989)	0.28
" Informed by these measurements, we built a pharmacokinetic model that quantitatively predicts microbiome contributions to systemic drug and metabolite exposure, as a function of bioavailability, host and microbial drug-metabolizing activity, drug and metabolite absorption, and intestinal transit kinetics."	( Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Goodman, AL; Wegmann, R; Zimmermann, M; Zimmermann-Kogadeeva, M, 2019)	0.51

Excerpt	Reference	Relevance
"The antiviral activity and cytotoxicity of (E)-5-(2-bromovinyl)-2'-deoxycytidine (BrVdCyd) against herpes simplex virus type 1 (HSV-1), singly and in combination with deaminase inhibitors was determined using rabbit kidney (RK-13), HEP-2, BHK-21 and VERO cells."	( Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2'-deoxycytidine in combination with deaminase inhibitors. Aduma, PJ; De Clercq, E; Gupta, SV, 1990)	0.28
"The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined by the plaque-reduction and infectious center assay methods."	( Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro. Biron, KK; Elion, GB, 1982)	0.26
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
" Moreover, the cells expressing Dm-dNKmut exhibited increased sensitivity in combination with BVDU, with induction of apoptosis in vitro and in vivo."	( Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine. Gu, M; Ma, S; Zhang, NQ; Zhao, L; Zheng, XY, 2012)	0.59
" The cytotoxicity and bystander effects of Dm‑dNK combined with cytotoxic nucleoside analogs were both observed in Dm‑dNK+ keloid fibroblasts."	( Efficacy of lentivirus‑mediated Drosophila melanogaster deoxyribonucleoside kinase combined with (E)‑5‑(2‑bromovinyl)‑2'‑deoxyuridine or 1‑β‑D‑arabinofuranosylthymine therapy in human keloid fibroblasts. Gu, M; Jiang, H; Sun, Y; Zheng, X, 2018)	0.48
"In the current report we present the case of a patient experiencing a life-threatening drug-drug interaction involving the concurrent administration of capecitabine and brivudine."	( A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer. Antoniadou, V; Diamantopoulos, P; Gogas, H; Halioti, A; Mantzourani, M; Papaxoinis, G; Tsifi, A, )	0.56

Excerpt	Reference	Relevance
" To increase bioavailability of these compounds, synthesis of their structurally diverse ester prodrugs was carried out: alkoxyalkyl (hexadecyloxypropyl, octadecyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM), 2,2,2-trifluoroethyl, butylsalicylyl, and prodrugs based on peptidomimetics."	( Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. Andrei, G; Balzarini, J; Brehová, P; Cihlar, T; De Clercq, E; Dracínský, M; Holý, A; Hui, H; Krecmerová, M; Laflamme, G; Masojídková, M; Naesens, L; Neyts, J; Pohl, R; Pomeisl, K; Snoeck, R; Tichý, T, 2010)	0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" At the end of the dosing period, 4 dogs/sex/dosage were sacrificed and complete gross and microscopic examinations performed."	( The chronic toxicity of bromovinyldeoxyuridine in beagle dogs. Chengelis, CP; Dickie, BC; Port, CD, 1988)	0.27
" No toxic side-effects could be attributed to the drug at the dosage used."	( Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients. De Clercq, E; Wildiers, J, 1984)	0.27
", day 0 or 2 (or day 4, if BVDU was administered subcutaneously) postinfection, at a dosage of 80 mg/kg per day or higher."	( Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice. de Clercq, E; Sim, IS; Zhang, ZX, 1982)	0.26
" Brivudin has a markedly higher anti-VZV potency than oral acyclovir, valacyclovir and famciclovir and thus offers a simpler dosing regimen."	( Herpes zoster guideline of the German Dermatology Society (DDG). Doerr, HW; Friese, K; Gross, G; Guthoff, R; Malin, JP; Pau, HW; Schöfer, H; Timm, A; Wassilew, S; Wutzler, P, 2003)	0.32
" Furthermore, the superior pharmacokinetics and more convenient dosing regimens with the use of valaciclovir and famciclovir clearly make them the preferred treatment option."	( Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. de Kock, J; McDonald, EM; Ram, FS, 2012)	0.38

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	56.2341	0.0032	45.4673	12,589.2998	AID2517
Chain A, Cruzipain	Trypanosoma cruzi	Potency	3.1623	0.0020	14.6779	39.8107	AID1476
AR protein	Homo sapiens (human)	Potency	19.9620	0.0002	21.2231	8,912.5098	AID743040; AID743042; AID743054
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	0.0251	0.0355	20.9770	89.1251	AID504332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	25.1189	0.5406	17.6392	96.1227	AID2364; AID2528
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	84.9214	23.9341	23.9341	23.9341	AID1967
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	11.8832	0.0003	23.4451	159.6830	AID743067
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	14.1254	0.0501	27.0736	89.1251	AID588590
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.5103	0.0056	12.3677	36.1254	AID624032
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	25.1189	0.0158	12.3113	615.5000	AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Thymidine kinase	Macacine alphaherpesvirus 1	IC50 (µMol)	32.3000	0.1500	2.5750	4.2000	AID326127
Thymidine kinase, cytosolic	Homo sapiens (human)	Ki	0.1000	0.0900	1.5213	7.0000	AID210688
Thymidine kinase	Human alphaherpesvirus 1 strain SC16	IC50 (µMol)	1,435.1500	0.1000	1.8491	7.9433	AID210531; AID210698
Thymidine kinase	Human alphaherpesvirus 1 (Herpes simplex virus type 1)	Ki	0.2400	0.2400	0.2400	0.2400	AID326128
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
nucleobase-containing compound metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
protein homotetramerization	Thymidine kinase, cytosolic	Homo sapiens (human)
DNA synthesis involved in mitotic DNA replication	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
thymidine kinase activity	Thymidine kinase, cytosolic	Homo sapiens (human)
protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
ATP binding	Thymidine kinase, cytosolic	Homo sapiens (human)
zinc ion binding	Thymidine kinase, cytosolic	Homo sapiens (human)
identical protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Thymidine kinase, cytosolic	Homo sapiens (human)
cytosol	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1277)

Assay ID	Title	Year	Journal	Article
AID634748	Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID161459	Antiviral activity against Vaccinia virus in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID665388	Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines.
AID1457769	Cytotoxic activity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID296675	Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID303210	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID260291	Antiviral activity against TK+ VZV OKA in human embryonic lung cells	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.
AID84072	Compound was evaluated for antiviral activity against HSV-1(strain KOS)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID303214	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID229025	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1652586	Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID63767	The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID161451	Antiviral activity against 196 strain of herpes simplex virus-2 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID82532	50% Cytostatic concentration required to inhibit human erythroleukemic (HEL) cell proliferation	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID463989	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID81189	Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID167881	Antiviral Activity against herpes simplex virus-2 (196) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID434310	Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID165523	Concentration of compound required to inhibit [1',2'-3H]dUrd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID1572736	Antiviral activity against Human cytomegalovirus Davis assessed as reduction in virus-induced cytopathogenicity by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1294502	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID167879	Antiviral Activity against herpes simplex virus-1 TK- VMW 1837 in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID82896	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID1230101	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID303213	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID66790	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1652587	Antiviral activity against HIV2 ROD infected in human TK-deficient CEM/TK(-) cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID85716	Antiviral activity against Herpes Simplex Virus-1(KOS)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID81037	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain; Not determined	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID1410511	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID87979	Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1(thymidine kinase deficient) in PRK cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID419596	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID64103	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1 (KOS) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID151172	Minimum cytotoxic concentration that causes alterations of VZV infected Osteosarcoma cell morphology	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID1498126	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID309810	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID434321	Cytotoxicity against african green monkey Vero cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID83207	The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID280203	Cytotoxicity against E6SM cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1427837	Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method
AID1462038	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID156707	Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID482705	Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID217971	Compound was tested for antiviral activity against Vaccinia virus in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID658740	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID217594	In vitro antiviral activity was determined by plaque-reduction assay in HSV-2 (strain G) infected Vero cell monolayers	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	Nucleosides. 129. Synthesis of antiviral nucleosides: 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracils.
AID156710	Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID218000	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vaccinia virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID85127	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID85718	Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (F cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID66779	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd and 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID105822	Minimum inhibitory concentration required to reduce cytopathogenicity of Cytomegalovirus Virus (CMV) in MRC-5 cells by 50%.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID156694	Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID296672	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID539915	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1572735	Antiviral activity against Human cytomegalovirus AD169 assessed as reduction in virus-induced cytopathogenicity by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID246464	Concentration required to inhibit Varicella-Zoster virus (strain OKA) induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID218132	Evaluation of antiviral activity against Vaccinia virus	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID257895	Antiviral activity against Reovirus 1 in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID516964	Cytotoxicity against HEL	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID63619	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain McIntyre induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID539917	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID85113	Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID216388	Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID66000	Tested for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in human embryonic skin muscle (E6SM) fibroblast cell cultures.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID65705	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID217899	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID81203	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus TK- VZV (07-1) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID167150	Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID257889	Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1710790	Antiviral activity against Herpes simplex virus 1 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID216479	Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50%	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID84230	Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID105823	Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID84420	Compound was tested for antiviral activity against herpes simplex virus( HSV-1-McIntyre) strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID120303	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 25 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID280188	Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID303232	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID260294	Cytotoxicity against HEL cells	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.
AID1394846	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID81053	Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID209532	Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID257893	Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1402824	Antiviral activity against TK-positive VZV Oka infected in HEL cells assessed as reduction in plaque formation after 5 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID120297	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 2.5 mg/kg per day; NT=Not tested	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID87197	Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (KOS) virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID220079	Antiviral activity against YS strain of thymidine kinase positive(TK+) Varicella-Zoster Virus (VZV)	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID218519	Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	S-glucosylated hydantoins as new antiviral agents.
AID275067	Antiviral activity against HSV1 KOS in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1251995	Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides.
AID64084	Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID84225	Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID687667	Cytotoxicity against HEL after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID167744	Antiviral Activity against herpes simplex virus-1 (F) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID44365	Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay.	1999	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6	Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID63609	Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID383516	Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID88195	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID84240	Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID1462036	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID675211	Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID83192	Minimum inhibitory conc. for 50% inhibition of TK-VZV (YS/R) virus plaque formation in HEL cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID1427825	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as reduction in virus plaque formation
AID210531	Inhibitory concentration against Herpes simplex virus type 1 thymidine kinase(HSV-1 TK)	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors.
AID167883	Antiviral Activity against herpes simplex virus-2 (G) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID553343	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID383507	Antiviral activity against vesicular stomatitis virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID86208	Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID303234	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID482712	Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID291032	Cytotoxicity against HEL cells assessed as cell growth after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID218385	Cytotoxic activity against vero cells was evaluated.	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID216247	Minimum inhibitory concentration required to reduce vesicular stomatis virus-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID209957	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in T-21 (LR) cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID118654	Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when administered intraperitoneally at 100 mg/kg per day after 39 days	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID419591	Cytotoxicity against human HEL cells assessed as alteration in cell morphology	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID216475	Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50%	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID86207	Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID63751	Tested for the minimum inhibitory concentration required to reduce thymidine kinase deficient herpes simplex virus type 1 (TK- HSV-1) strain B2006 induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID1337440	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID96607	Compound was tested for antitumor activity against L1210 cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID63623	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-2) strain G induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID85373	Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID216300	Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain 07	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID432172	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID133911	Mean time survival (MTS) of the mice at the end of 28 or 49 days.	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID85405	Antiviral activity against HSV-1 kinase mutant resistant to SCS(parental) was determined at a conc of 30 uM	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID539914	Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID434308	Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID87507	Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain KOS.	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID167884	Antiviral Activity against herpes simplex virus-2 (Lyons) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID221459	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains Lyons	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID432176	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID87978	Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1 in PRK cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID68278	Inhibitory concentration required for morphologic alteration in normal cell in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID1410504	Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID224702	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 9	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID65709	Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID156706	Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID111522	Tested for the appearance of skin lesions or paralysis of the legs after 52 days when applied topically at 10% after 52 days	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID83047	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human embryonic HEL cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID85253	Compound was evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) MS strain by using plaque reduction assay.	1999	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6	Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID1394852	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID63592	Minimum inhibitory conc. for 50% inhibition of HSV-1 (KOS) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID766699	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID83049	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human embryonic HEL cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID216200	Tested for cytotoxic activity in African green monkey kidney cells (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID110459	Cumulative mortality in percent of HSV-1 infected mice, after peroral administration of 100 mg/kg of compound	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87191	Concentration that protects by 50% the cytopathic effect induced by herpes simplex virus - 1.	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity.
AID416777	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1684810	Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1572730	Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID216158	Anti-viral activity which is required for the inhibition of VZV (Varicella zoster virus )	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and antiviral activity of 3'-deoxy-3'-C-hydroxymethyl nucleosides.
AID284531	Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID81032	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID218133	Antiviral activity against vaccinia virus	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID66783	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID569239	Cytotoxicity against HEL cells after 3 days by coulter counter analysis	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID66958	Effective concentration to show 50% of activity was measured on Epstein Barr virus(EBV) cell culture	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID766703	Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID432171	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID326135	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID1572734	Antiviral activity against thymidine kinase deficient Varicella-zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1854968	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID1684812	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID260292	Antiviral activity against TK- VZV 07/10 in human embryonic lung cells	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.
AID280941	Cytotoxicity against mouse L1210/0 cells after 48 hrs	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID42109	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BS-C-1A cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID634755	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID64114	Minimum inhibitory concentration required to to cause a microscopically detectable change in normal cell morphology	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID65708	Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID393981	Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID227702	Ratio of ID50 for dThd or dUrd incorporation to ID50 for HSV-1, HSV-2 or VV(whatever was lowest)	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID1328758	Cytostatic activity against human HeLa cells after 3 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID167886	Antiviral Activity against vaccinia virus in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID228285	Cytotoxic concentration that produces 50% inhibition of cell growth.	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID482702	Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID66004	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID217757	In vitro antiviral activity against HSV-1(strain HFEM) in Vero cells	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Synthesis and antiviral properties of 5-(2-substituted vinyl)-6-aza-2'-deoxyuridines.
AID1462033	Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID66939	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID280204	Cytotoxicity against HeLa cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID68124	Concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID120295	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 10 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID66769	The compound was tested for its antiviral activity against HSV-2 (Lyons) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID84256	Compound was evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) VR-3 strain by using plaque reduction assay.	1999	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6	Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID553338	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID1251996	Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides.
AID217905	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID83535	Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID66770	The compound was tested for its antiviral activity against TK-HSV-1 (B2006) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID120298	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 50 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID611615	Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID675210	Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID120293	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through at a dose 25 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID291029	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA assessed as reduction of plaque formation	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID1498127	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus infected in HEL cells assessed as reduction in virus plaque formation	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID434319	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID86023	Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID1854967	Antiviral activity against thymidine kinase deficient Varicella zoster-virus O7-1 strain infected in HEL cells assessed as reduction in plaque formation by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID217489	Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID1337434	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID1854963	Antiviral activity against thymidine kinase deficient mutant Acyclovir resistant HSV-1 KOS strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID1409609	Cytotoxicity of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID84588	Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1)	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID209539	Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID156685	Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID85559	Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID434315	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID87826	Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain 196.	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID432170	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID464178	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID258994	Cytotoxic activity against cultured human embryonic lung (HEL) cells	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID85423	Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID392512	Antiviral activity against Herpes simplex virus 2	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID280180	Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID607907	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID383527	Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID87147	Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID120299	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 5 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID768207	Cytotoxicity against human HEL cells	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1661187	Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID392515	Antiviral activity against Human cytomegalovirus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID434307	Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID482707	Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID83332	The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1462039	Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID167140	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vesicular stomatitis virus	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID1409608	AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID87322	Antiherpes activity was tested as percent of control of plaque-formation against HSV-2 (333) virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID275087	Cytotoxicity against HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID291037	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID85717	Antiviral activity against Herpes Simplex Virus-1 (McIntyre)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID224695	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 6	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID66005	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID83183	Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID1457770	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID64108	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (G) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID68121	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID464181	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID63597	Minimum inhibitory conc. for 50% inhibition of HSV-2 (Lyons) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID1427827	Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as alteration in cell morphology by microscopic method
AID85374	Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID288940	Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -b cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID167887	Antiviral Activity against vesicular stomatitis virus in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID275071	Antiviral activity against Coxsackie B4 virus in HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID383531	Antiviral activity against Reo virus 1 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID217904	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID297312	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID81898	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HEp-2M cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID229235	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID291036	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID1684811	Selectivity index, ratio of CC50 for human HEL cells to EC50 for antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID296679	Cytotoxicity against HEL cells after 3 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID66942	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID393982	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID1410507	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 assessed as inhibition of plaque formation measured after 5 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID1325061	Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.
AID83897	Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (McIntyre)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID222129	Minimum concentration required to cause a microscopically detectable alteration of cell morphology	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID87194	Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (CL101) virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID156709	Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID90777	Antiviral activity against human cytomegalovirus Davis which reduces virus plaque formation by 50%; ND denotes no data	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID280193	Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID224696	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 9	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID482710	Cytotoxicity against human HeLa cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID83044	Tested for cytotoxic activity in human embryonic lung fibroblast (HEL)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID218513	Effective concentration required to reduce vesicular stomatitis virus (VSV)-induced cytopathicity in vero cells	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID65710	Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID167747	Antiviral Activity against herpes simplex virus-1 (McIntyre) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID1230104	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID81038	The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID1113471	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID286286	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus.
AID85828	Antiviral activity against herpes simplex virus type 1 (HSV-1) determined in baby hamster kidney cells	1983	Journal of medicinal chemistry, Sep, Volume: 26, Issue:9	Structural requirements of olefinic 5-substituted deoxyuridines for antiherpes activity.
AID516966	Antiviral activity against acyclovir-resistant HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID297316	Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID216153	Effective concentration against TK+ Varicella-Zoster Virus (VZV) OKA strain	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID246311	Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID291031	Cytotoxicity against HEL cells assessed as cell morphology after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID1727355	Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups.
AID217419	Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID429201	Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
AID81028	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID63748	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 2 (HSV-2) strain 196 induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID429202	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
AID221799	Compound was tested for antitumor activity against thymidine kinase deficient human B-lymphoblast Raji/0 cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID516962	Cytotoxicity against HEL assessed as change in cell morphology	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID84086	Minimum inhibitory concentration was determined against HSV-1 (G) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID81058	Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID304888	Inhibition of VZV-TK catalyzed dThd phosphorylation	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID1337433	Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID68252	Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID85884	50% effective concentration required to reduce herpes simplex virus-2 (HSV-2 G strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID85378	Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID607906	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID87444	Concentration that induces 50% cell toxicity was determined using monolayers of uninfected HeLa cells	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Uridine 5'-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity.
AID83046	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human embryonic HEL cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID718735	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID64105	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1( F) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID210698	Binding affinity towards HSV-1 thymidine kinase	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	Understanding the binding of 5-substituted 2'-deoxyuridine substrates to thymidine kinase of herpes simplex virus type-1.
AID383509	Antiviral activity against respiratory syncytial virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID280197	Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID284539	Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID246308	Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID224699	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 20	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID1782673	Antiviral activity against thymidine kinase deficient Varicella zoster virus	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID303229	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID658618	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID45814	Dose that inhibited 50% cell growth of human T-lymphoid CEM cells compared with untreated control	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID83331	The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1869612	Antiviral activity against VZV TK+ infected in HEL cells assessed as reduction in virus plaque formation	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID218254	Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID85420	Compound was tested for antiviral activity against herpes simplex virus( HSV-2-lyons) strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID611617	Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1462034	Antiviral activity against wild type thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of virus-induced plaque formation	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID634751	Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID482704	Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1337435	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus YS-R infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID303236	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID28488	Catalytic rate constant was determined; ND: Not determined	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID257890	Antiviral activity against Herpes simplex virus 2 G strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID245891	Cytotoxic concentration required to reduce HEL cell growth	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID85372	Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID1427831	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
AID68123	Concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID87842	Effect on thymidine kinase in the herpes simplex type-1 infected cells	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID434306	Cytotoxicity against human HeLa cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID217760	Cytotoxicity was measured by determining the incorporation of [methyl-3H]thymidine into DNA of Vero cells	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Synthesis and antiviral properties of 5-(2-substituted vinyl)-6-aza-2'-deoxyuridines.
AID607912	Cytotoxicity against cat CRFK cells by colorimetric formazan-based MTS assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID63762	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID216408	Antiviral activity against vesicular stomatitis virus	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID1113470	Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID64109	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (Lyons) was measured.	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID246414	Concentration required to inhibit herpes simplex virus type 1 induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID84950	Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID303224	Cytotoxicity against HEL cells assessed as cell growth after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID63948	Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID85720	Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (McIntyre cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID1498113	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1869613	Antiviral activity against VZV TK- infected in HEL cells assessed as reduction in virus plaque formation	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID611621	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID221320	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains McIntyre	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID1409614	Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1661191	Cytotoxicity against human HEL cells assessed as minimum cytotoxic concentration for change in cellular morphology incubated for 3 days by microscopic analysis	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID165784	Inhibitory activity against Raji cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID216346	Tested for antiviral activity against Punta toro virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID416775	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID217806	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID303233	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID63602	Minimum inhibitory concentration required to effect a microscopically visible change of cell morphology in human embryonic skin-muscle (E6SM) cell culture.	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID216303	Compound was evaluated for the inhibition of VZV strains of YS	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID217659	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID687661	Antiviral activity against HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID246626	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID217510	Minimum inhibitory concentration required to reduce Varicella-Zoster virus (VZV (Oka)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID246470	Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID463991	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1394851	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID246532	Concentration required to inhibit human immunodeficiency virus-1 (strain IIIb) induced cytopathogenicity in CEM cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID84762	Antiviral activity against Herpes Simplex Virus-2(Lyons)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID217503	cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID90775	Antiviral activity against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%; ND denotes no data	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID111521	Tested for the appearance of skin lesions or paralysis of the legs after 39 days when administered intraperitoneally at 100 mg/kg per day	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID687663	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID216539	Evaluation of antiviral activity against Vesicular stomatitis virus.	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID387854	Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID280195	Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID244773	Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID218374	Inhibitory dose required to reduce the growth of vero cells by 50% over a 4 day period.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID87843	Antiviral activity against herpes simplex type-1 expressed as ED50	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID85883	50% effective concentration required to reduce herpes simplex virus-1 (HSV-1 KOS strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID383532	Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID84760	Antiviral activity against Herpes Simplex Virus-2(196)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID217483	Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID482709	Cytotoxicity against human E6SM cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID87827	Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID85120	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID634831	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID216302	Compound was evaluated for the inhibition of VZV strains of OKA	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID218511	Effective concentration required to reduce reovirus-1-induced cytopathicity in vero cells	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID83052	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human embryonic HEL cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID304886	Cytotoxicity against HEL cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID1394845	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID1652588	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
AID221325	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains 196	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID1382164	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID675222	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID297319	Antiviral activity against Sindbis virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID1382169	Selectivity index, ratio of CC50 for HEL cells to EC50 for Varicella zoster virus Oka infected in HEL cells	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID1462040	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID297315	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID81056	Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID288916	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID553337	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID607916	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID221967	Compound was tested for antitumor activity against human T-lymphoblast Molt/4F cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID280205	Cytotoxicity against Vero cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1410503	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID217657	Minimum inhibitory concentration was determined against VZV (YS) in HEL cells	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID217508	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID607908	Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID216347	Tested for antiviral activity against Reo-1 virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID280179	Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID245943	Concentration required to inhibit cell proliferation in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID87984	Minimum inhibitory concentration which is active against herpes simplex virus type-1 (HSV-1); value ranges from 0.007-0.01 ug/mL	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and antiviral activity of 3'-deoxy-3'-C-hydroxymethyl nucleosides.
AID217829	Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID83182	Concentration required to reduce VZV-YS/R-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID284535	Cytotoxicity against E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID257901	Antiviral activity against Vesicular stomatitis virus in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID388919	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID569234	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID1610166	Antiviral activity against Vaccinia virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID258991	Antiviral activity against Varicella-Zoster virus YS/R strain	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID768204	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID217484	Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID297314	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID66780	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID464180	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID634833	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1409607	IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID548425	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID63598	Minimum inhibitory conc. for 50% inhibition of TK HSV-1 (B2006) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID224704	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 12	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID66002	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID209374	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain VMW 1837	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID235596	Ratio of ID50/ID90 in HSV-2 infected cells	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID63593	Minimum inhibitory conc. for 50% inhibition of HSV-1 (McIntyre) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID87299	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of specified concentrations of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID309814	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID82551	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID280200	Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID83526	Anti-VZV activity against YS TK+ in HEL cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID63760	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID87821	Antiviral activity expressed as minimum HSV-2 (Lyons) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID280192	Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1230099	Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID66775	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dUrd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID718734	Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID66938	Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID66773	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of Urd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1328757	Cytostatic activity against thymidine kinase deficient human CD4-positive CEM cells after 3 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID165527	Concentration required to reduce Herpes simplex virus type 2 induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID167137	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (G)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID658741	Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID303212	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID280189	Antiviral activity against HIV1 3B in human CEM cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID81024	The compound was tested for anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells;d ='not determined'	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID383510	Cytotoxicity against human E6SM cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID83198	Minimum inhibitory concentration required for antiviral activity to reduce TK Varicella Zoster virus (VZV) (07/1) induced cytopathicity in human embryonic lung cells (HEL)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID658755	Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID303209	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID85418	Compound was tested for antiviral activity against herpes simplex virus( HSV-2-196 strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID63599	Minimum inhibitory conc. for 50% inhibition of alteration of morphology in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID66767	The compound was tested for its antiviral activity against HSV-2 (196) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID63757	The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID161457	Antiviral activity against McIntyre strain of herpes simplex virus-1 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID84766	Antiviral activity against Herpes Simplex Virus-2(Lyons)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID482715	Cytotoxicity against african green monkey Vero cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID393979	Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID432169	Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID665385	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines.
AID167877	Antiviral Activity against herpes simplex virus-1 TK- B2006 in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID85714	Antiviral activity against Herpes Simplex Virus-1 (McIntyre)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID569238	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID68256	Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID246314	Concentration required to inhibit vaccinia virus induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID291030	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 assessed as reduction of plaque formation	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID548423	Cytotoxicity against human HEL cells assessed as altered cell morphology	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID304887	Cytotoxicity against HEL cells	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID221326	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains G	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID1727353	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups.
AID63765	The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID83022	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID284540	Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID217674	Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID383515	Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID112441	Inhibitory activity against incorporation of deoxy-[methyl.3H-]-thymidine (dThd) into the DNA of murine leukemia L1210 cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID1457768	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of plaque formation	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1782676	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID392511	Antiviral activity against Herpes simplex virus 1	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID66003	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID84243	Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID86492	Tested for antiviral activity against coxsackie-B4 virus in human epithelial cell line	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID634756	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID607919	Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID1684815	Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 6 to 7 post-viral infection	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID84604	Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID85112	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID72044	Inhibitory activity against FM3A/0 cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID1251997	Cytotoxicity against Varicella zoster virus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides.
AID66020	Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against KOS,F,McIntyre strains of HSV-1 virus.	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.
AID383523	Antiviral activity against Coxsackie virus B4 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID216533	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vesicular stomatitis virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID85402	Antiviral activity against HSV-1 kinase mutant resistant to B3(BVdU) was determined at a conc of 30 uM	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID85379	Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID85421	Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID85407	Antiviral activity against HSV-1 kinase mutant resistant to Tr7(ACV) was determined at a conc of 30 uM	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID482711	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID718736	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID106002	Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID167746	Antiviral Activity against herpes simplex virus-1 (KOS) in rabbit kidney cell	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID120302	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 2.5 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID83195	Minimum inhibitory conc. for 50% inhibition of growth in HEL cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID63607	Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1710792	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID63591	Minimum inhibitory conc. for 50% inhibition of HSV-1 (F) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID675216	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID66777	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID216509	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in vero cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81025	The compound was tested for anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells;d ='not determined'	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID387602	Cytotoxicity against human HeLa cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID416772	Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID167139	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vaccinia virus	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID156702	Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1610151	Antiviral activity against thymidine kinase deficient Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID64120	Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID463993	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID87993	Effect on thymidine kinase in the herpes simplex type-2 infected cells	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID87153	Evaluated for minimum inhibitory concentration against HeLa cells (human carcinoma) infected with VSV, Coxs, B4, polio-1 virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID66934	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of specified concentrations of benzylacyclouridine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID303221	Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID167135	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (McIntyre)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID1410506	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka assessed as inhibition of plaque formation measured after 5 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID217888	Antiviral activity against HSV-1 (Brand) in Vero cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID434313	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID64089	Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID66006	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID134101	Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID1382163	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID64087	Concentration required to inhibit HSV-2(196) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID280176	Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID658617	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1610154	Cytotoxicity against human HELF cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1337442	Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID217758	In vitro antiviral activity against HSV-2(strain 196) in Vero cells	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Synthesis and antiviral properties of 5-(2-substituted vinyl)-6-aza-2'-deoxyuridines.
AID1661189	Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID1652585	Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as inhibition of viral-induced giant cell formation incubated for 4 to 5 days by microscopy
AID296678	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID634754	Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID539918	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1462031	Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID63604	Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID553336	Cytotoxicity against human HEL cells after 3 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID309812	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID120296	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 1 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID217889	Antiviral activity against HSV-2 (K979) in Vero cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID463990	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID463992	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID221319	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains KOS	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID280191	Antiviral activity against MSV in mouse C3H cells assessed as inhibition of virus-induced transformation after 6 days	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID83329	The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID84217	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID83194	Minimum inhibitory conc. for 50% inhibition of VZV (YS) virus plaque formation in HEL cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID634838	Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID81191	Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID85556	Antiviral activity against various strains of Herpes Simplex virus type I	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral properties of some 2'-deoxy-5-(fluoroalkenyl)uridines.
AID232770	Selectivity index against HSV-1 was determined as CD50/ED50 ratio	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	S-glucosylated hydantoins as new antiviral agents.
AID766700	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1422441	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID83197	Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (Davis) induced cytopathicity in human embryonic lung cells (HEL)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID87828	Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain Lyons	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID66781	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd and 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID288918	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID284529	Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID217421	Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID1610163	Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID210688	Binding affinity constant against HSV-1 thymidine kinase	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID72045	Compound was tested for antitumor activity against FM3A/0 mammary carcinoma cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID607915	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID383522	Cytotoxicity against african green monkey Vero cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID161455	Antiviral activity against KOS strain of herpes simplex virus-1 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID63768	The minimum inhibitory concentration was measured on E6SM cells for morphological alteration	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID66007	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID1113469	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID326138	Cytotoxicity against african green monkey Vero cells after 2 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID85715	Antiviral activity against Herpes Simplex Virus-1(F)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID81200	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus VV was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID326132	Activity of Herpes B virus recombinant thymidine kinase at 1 mM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID275072	Antiviral activity against RSV in HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID217504	Minimal cytotoxic concentration, the concentration required to cause a microscopically visible alteration of normal cell morphology.	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID257897	Antiviral activity against Coxsackie virus B4 in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1382173	Antiviral activity against Human simplex virus 2 G infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID258992	Antiviral activity against human cytomegalovirus AD169 strain	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID1427826	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as reduction in virus plaque formation
AID66788	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID84418	Compound was tested for antiviral activity against herpes simplex virus( HSV-1-KOS) strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID65712	Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID66786	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd and 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1854966	Antiviral activity against Varicella zoster-virus OKA strain harboring thymidine kinase infected in HEL cells assessed as reduction in plaque formation by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID634759	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID569232	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID167889	Evaluated for the minimum cytotoxic concentration (MCC) upon preincubation of rabbit kidney cells in medium containing 10% fetal calf serum at 37 degree Celsius for 24 hr	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID309813	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID1402829	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID217663	Compound was evaluated for the antiviral activity against Varicella-Zoster virus (VZV) Oka strain by using plaque reduction assay.	1999	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6	Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID1361088	Cytostatic activity against human HEL cells after 3 days by coulter counter method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation.
AID553342	Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID218227	Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID1402826	Antiviral activity against HSV1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID103155	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in M-21 (GM137) cell line,	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID275070	Antiviral activity against vesicular somatitis virus in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1382171	Antiviral activity against Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID52056	Minimum inhibitory concentration required to reduce virus-induced cell growth by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID209373	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain B2006	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID1394850	Cytostatic activity against HEL cells after 3 days by Coulter counting method	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID1361087	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation after 5 days	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation.
AID1572732	Cytotoxicity against HEL cells assessed as effect on cell morphology at 0.32 to 200 uM by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1782698	Antiviral activity against Varicella zoster virus assessed as inhibition of viral replication	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID1498115	Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID83524	Anti-VZV activity against OKA strain TK+ in HEL cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID65516	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E1SM cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID84417	Compound was tested for antiviral activity against herpes simplex virus( HSV-1-F) strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID87159	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against respiratory syncytial virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID569233	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID1727352	Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus-induced cytopathogenic effect measured after 3 days coulter counter method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups.
AID63947	Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID291033	Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID246450	Concentration required to inhibit human cytomegalovirus strain AD169 induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID84953	Compound was evaluated for antiviral activity against HSV-2(strain G)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID217648	Minimum inhibitory concentration was determined against VZV (OKA) in HEL cells	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID634761	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1854965	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID658619	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID217807	Minimum inhibitory concentration required to reduce vaccinia virus-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID85422	Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID634832	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID87160	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID309811	Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID634747	Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID65844	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID45931	Inhibitory concentration against CMV strain AD169 in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID297320	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID83522	Anti-VZV activity against 07/1 TK- in HEL cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID718738	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID90761	50% effective concentration required to reduce cytomegalovirus (CMV Davis strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID216473	Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50%	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID1410510	Cytotoxicity against HEL cells assessed as morphological changes after 3 days by microscopic analysis	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID84239	50% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK-) VMW 1837 strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID83146	Antiviral activity against VZV (Ellen) in human lung fibroblast (HLF-1) cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID216301	Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain YS-R	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID134099	Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID303238	Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID84223	Effective concentration to show 50% of activity was measured on herpes simplex virus-1 KOS strain cell culture.	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID71873	Inhibitory activity against FM3A TK- cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID84590	Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID1382167	Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic method	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID284527	Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID156542	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in PRK cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID634749	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID84963	Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (196)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID304885	Antiviral activity against TK- VZV YS in HEL cells after 5 days	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID83035	Minimum cytotoxic concentration to reduce the HEL cell proliferation by 50%	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID1113467	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID64085	Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID257886	Antiviral activity against HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1457765	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1410505	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID161458	Antiviral activity against VMW 1837 strain of thymidine kinase deficient (TK-) herpes simplex virus-1 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID83716	Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID63945	Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1684816	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID257898	Antiviral activity against Punta Toro virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID280198	Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID72158	Inhibitory activity against FMBA TK-/HSV-2 TK+ cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID161454	Antiviral activity against G strain of herpes simplex virus-2 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID165542	Inhibitory activity against incorporation of deoxy-[1',2'-3H]uridine (dUrd) into the DNA of uninfected primary rabbit kidney (PRK) cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID434311	Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID326134	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID482708	Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID766697	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1402827	Antiviral activity against acyclovir-resistant HSV1 KOS harboring TK- mutant infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID86500	The compound was tested for antiviral activity against VSV-virus in human epithelial cells	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID84961	Minimum inhibitory concentration against HSV-2.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID1230103	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID63755	Tested for the minimum inhibitory concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50%	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID88278	Evaluated for minimum inhibitory concentration against TK-B2006 strain of Herpes simplex virus (HSV-1) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID1294506	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID611624	Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID81196	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- VZV virus in HEL cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID217480	Minimum inhibitory concentration required to reduce VSV virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID217654	Minimum inhibitory concentration was determined against VZV (TK-YS/R) in HEL cells	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID63764	The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID216540	Antiviral activity against vesicular stomatitis virus	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID83325	The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (Davis strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID81757	Minimum toxic effect against HEp-2 cells.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID156705	Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID217488	Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID216348	Tested for antiviral activity against Sindbis virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID303235	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1294503	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID766698	Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID85432	Inhibition constant against HSV-1 TK	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID766704	Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1337439	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID84965	Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (Lyons)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID66001	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID326127	Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID326128	Inhibition of Herpes simplex virus 1 recombinant thymidine kinase	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID634834	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1337441	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID1382174	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID548428	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID64117	Tested for minimum inhibitor concentration against vesicular stomatitis virus (VSV) in E6SM cells.	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID85246	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HSF (VGS) cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID86216	Antiviral activity against HSV-2 (K979) in human epithelial (Hep-2) cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID83191	Minimum inhibitory conc. for 50% inhibition of TK VZV (07/1) virus plaque formation in HEL cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID87824	Minimum inhibitory concentration required to reduce HSV-2 (G) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID634757	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID156701	Antiviral activity against HSV-2 (G) in Primary Rabbit Kidney (PRK) cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID86022	Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID81202	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus CMV (Davis) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID165526	Concentration required to reduce Herpes simplex virus type 1 induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID388921	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID275076	Antiviral activity against Punta Toro virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID85893	Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID1869614	Cytotoxicity against human HEL cells assessed as change in cell morphology measured after 3 days by coulter counting method	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID68118	Concentration required to cause a microscopically detectable alteration of normal ESM cell morphology.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID434314	Antiviral activity against RSV infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID156700	Antiviral activity against HSV-1 (KOS) in Primary Rabbit Kidney (PRK) cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID257888	Antiviral activity against HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID303211	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1422438	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID217593	In vitro antiviral activity was determined by plaque-reduction assay in HSV-1(strain 2931) infected Vero cell monolayers	1984	Journal of medicinal chemistry, Jan, Volume: 27, Issue:1	Nucleosides. 129. Synthesis of antiviral nucleosides: 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracils.
AID87995	Antiviral activity against herpes simplex type-2 expressed as ED90	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID134097	Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID766711	Cytotoxicity against human HEL cells assessed as morphological changes	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID675220	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID139990	Inhibition constant assumed to reflect the affinity for the transport site in mouse erythrocytes	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID88277	Evaluated for minimum inhibitory concentration against KOS, F, McIntyre strains of Herpes simplex virus (HSV-1) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID1394847	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID83500	Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID766696	Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1610164	Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1230102	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID83895	Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (F)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID81030	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID84761	Antiviral activity against Herpes Simplex Virus-2(G)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID288919	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID156686	Inhibitory concentration required to reduce incorporation of 2-deoxyuridine (dUrd) into DNA of Primary Rabbit kidney (PRK) cell cultures	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID464179	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID87994	Antiviral activity against herpes simplex type-2 expressed as ED50	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID569235	Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID221318	Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains F	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID82895	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID1661190	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID611622	Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID68122	Concentration required to reduce HSV-2(G) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID83528	Anti-VZV activity against YS/R TK- in HEL cells	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID84765	Antiviral activity against Herpes Simplex Virus-2(G)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID1328754	Cytostatic activity against mouse L1210 cells after 2 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID548424	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID84767	Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (196 cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID64090	Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID434312	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID81206	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus VZS (YS) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID85712	Antiviral activity against Herpes Simplex Virus-1 (F)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID1427833	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
AID246487	Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID383518	Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID83020	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID1661188	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID675213	Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID611626	Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID383530	Antiviral activity against Parainfluenza 3 virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID611625	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID81218	Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID218509	Effective concentration required to reduce coxsackie virus B4-induced cytopathicity in vero cells	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID66772	The compound was tested for its antiviral activity against vesicular stomatitis virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID83048	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human embryonic HEL cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID516967	Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID66943	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID83893	Minimum inhibitory concentration against HSV-1.	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID66766	The compound was tested for its antiviral activity against HSV-1 (McIntyre) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID84228	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID216155	Effective concentration against TK- Varicella-Zoster Virus (VZV) 07/1 strain	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID419592	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID288938	Inhibition of proliferation of thymidine kinase deficient OST cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID297321	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID516969	Antiviral activity against acyclovir-resistant VZV 07/1 infected in HEL assessed as reduction in virus-induce cytopathicity	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID224697	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 0	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID84415	Compound was tested for antiviral activity against herpes simplex virus (thymidine kinase deficient herpes simplex virus ( HSV-1 (B2006) in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID64111	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus TK- HSV-1 (VMW1837) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID675217	Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID1661192	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Amidate Prodrugs of
AID1251998	Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides.
AID1422440	Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID217819	Concentration required to reduce vaccinia virus induced cytopathogenicity in rabbit cell kidney culture	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID161452	Antiviral activity against B2006 strain of thymidine kinase deficient (TK-) herpes simplex virus-1 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID68119	Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(B2006) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID224693	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 20	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID516965	Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID83499	Cytotoxic concentration reducing HEL cell growth by 50%.	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID280178	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID280206	Cytotoxicity against C3H cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID209538	Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID1710791	Antiviral activity against Herpes simplex virus 2 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID83205	Tested for antiviral activity against thymidine kinase wild type Varicella zoster virus in human embryonic lung fibroblast	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID288917	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID120304	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 50 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID84768	Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (G cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID218512	Effective concentration required to reduce sindbis virus-induced cytopathicity in vero cells	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID326131	Activity of Herpes B virus recombinant thymidine kinase at 100 uM	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID224692	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 12	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID66795	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 3 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1869611	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus plaque formation	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID416773	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID84964	Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (G)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID304884	Antiviral activity against TK- VZV 07 in HEL cells after 5 days	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID383514	Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1854960	Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID221302	Compound was tested for antiviral activity against herpes simplex Vassicular stomatitis in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID665383	Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines.
AID66765	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID151170	Cytotoxic concentration that causes growth inhibition of VZV infected Osteosarcoma cells	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID257899	Antiviral activity against Respiratory syncytial virus in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID216410	Evaluated for minimum inhibitory concentration against Vesicular stomatitis virus (VSV) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID288939	Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -a cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1410508	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID304883	Antiviral activity against TK+ VZV YS in HEL cells after 5 days	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID84085	Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID118655	Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when applied topically at 10% after 52 days	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID84409	Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 of VMW 837	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID246562	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID607911	Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID87149	Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID156860	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of specified concentrations of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID297313	Antiviral activity against Parainfluenza 3 virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID434317	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID284538	Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID85419	Compound was tested for antiviral activity against herpes simplex virus( HSV-2-G) strain in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID68255	Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID167134	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (F)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID81049	Concentration required to cause 50% reduction in HEL cell growth.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID516968	Antiviral activity against acyclovir-resistant VZV OKA infected in HEL assessed as reduction in virus-induce cytopathicity	2010	Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19	Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
AID1402822	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID569231	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID165524	Concentration of compound required to inhibit [methyl-3H]dThd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID83534	Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID216172	Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS/R (TK-) strain.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID83184	Concentration required to reduce varicella zoster virus (VZV)YS-TK-PFU plaque formation by 50% in human embryonic lung (HEL) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID768206	Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID81219	Cytotoxicity concentration required to reduce cell growth by 50% in HEL	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID284537	Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID66789	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd and 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID275075	Antiviral activity against Sindbis virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID66778	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81035	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain; Not determined	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID718733	Toxicity in HEL cells assessed as induction of cell morphology changes	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID156704	Evaluation for antiviral activity against herpes simplex virus-1 (McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID63617	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain KOS induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID84071	Compound was evaluated for antiviral activity against HSV-1(TK-, strain B2006)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID86209	Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID244774	Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID1382166	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction in viral plaque formation	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID1610152	Antiviral activity against thymidine kinase positive Varicella zoster virus infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by Giemsa staining based microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID87823	Minimum inhibitory concentration required to reduce HSV-2 (196) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID658739	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID388922	Cytotoxicity against HEL cells assessed as morphological alteration after 3 days	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID68253	Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID105824	Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID675215	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID87157	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID548427	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID286285	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus.
AID156703	Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID218375	Cytotoxic dose of compound required to reduce the viability of normal uninfected vero cells by 50%.	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	S-glucosylated hydantoins as new antiviral agents.
AID383519	Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID66784	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd and 50 ug/mL of 6-aminothymine,	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID429196	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
AID43638	Antiherpes activity was tested as percent of control of plaque-formation against BVdUr virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID87506	Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain F	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID65995	Compound was evaluated for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology.	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.
AID607910	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID216349	Tested for antiviral activity against coxsackie B-4 virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID548426	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID217900	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against junin virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID63763	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1382168	Cytostatic activity against HEL cells after 3 days by Coulter counting method	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID275069	Antiviral activity against vaccinia virus in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID553339	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID71878	Concentration required to cause a microscopically detectable alteration of normal cell morphology	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID134100	Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID217420	Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID63601	Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID67101	Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV.
AID675218	Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID1230105	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID258989	Antiviral activity against Varicella-Zoster virus YS strain	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID134096	Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID156708	Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID718737	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID224707	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 6	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID392537	Antiviral activity against Varicella zoster virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID246523	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID64104	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1 (Mc Intyre) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID120300	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 100 mg/kg per day; NT=Not tested	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID66763	oncentration required to inhibit VV induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID388923	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID66787	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID611623	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID84084	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID216038	Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID1872793	Antiviral activity against VZV strain Oka bearing wild type thymidine kinase assessed as reduction in virus induced cytopathogenicity	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Recent applications of vinyl sulfone motif in drug design and discovery.
AID66933	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of specified concentrations of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87137	Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID280190	Antiviral activity against HIV2 ROD in human CEM cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID104933	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in MO cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66019	Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-2 virus as means of G, 196, and Lyons strains	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.
AID68257	Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID112423	Concentration required to reduce leukemia L1210 cell growth in mice	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID84407	Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 of Acyclovir	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID84218	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID607909	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID383517	Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID275068	Antiviral activity against HSV2 in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID280199	Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID134098	Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO)	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells.
AID81199	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus VSV was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID224694	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 3	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID63761	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID81204	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus TK- VZV (YS-R) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID634746	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID257887	Antiviral activity against vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID83034	Compound was evaluated for the cytotoxicity against HEL cells	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID217903	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID81197	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against VZV virus in HEL cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID63605	Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID634750	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1422437	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID1325059	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.
AID1402828	Antiviral activity against HSV2 strain G infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 2 to 3 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID246614	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
AID634835	Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID96824	Inhibitory activity against L1210 cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID3058	Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV)	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID275073	Antiviral activity against para influenza 3 virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID416776	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID383521	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID429198	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
AID87505	Minimum inhibitory concentration required to reduce HSV-1 (McIntyre) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID83896	Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (KOS)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID1854961	Antiviral activity against HSV-1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID63780	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID30875	Antiherpes activity was tested as percent of control of plaque-formation against ACG (Tr7) virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID687662	Antiviral activity against HSV2 G infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID246316	Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID303230	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID634753	Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID64110	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus TK- HSV-1 (B2006) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID607913	Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID228733	Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID64088	Concentration required to inhibit HSV-2(G) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID217497	Effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID221798	Compound was tested for antitumor activity against human B-lymphoblast Raji/0 cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID147625	Antiviral activity against OKA strain of thymidine kinase positive(TK+) Varicella-Zoster Virus (VZV)	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID66771	The compound was tested for its antiviral activity against vaccinia virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID687664	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID218510	Effective concentration required to reduce parainfluenza-3-induced cytopathicity in vero cells	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID66764	The compound was tested for its antiviral activity against HSV-1 (F) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1462037	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID1869615	Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID634760	Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1854969	Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID66799	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81201	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus CMV (AD169) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID675219	Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID416774	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID167133	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 ((KOS)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID393980	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID297317	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID209530	Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (B2006) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID66791	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd and 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81371	Inhibitory dose for HELF cell proliferation during 3-day treatment period	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID1610153	Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1498130	Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID216169	Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using 07/1 (TK-) strain.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID1394849	Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID429197	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
AID63766	The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID85129	Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID257891	Antiviral activity against Vaccinia virus in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID257894	Antiviral activity against Parainfluenza-3 virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID246529	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID63595	Minimum inhibitory conc. for 50% inhibition of HSV-2 (196) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID291034	Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID83201	Minimum inhibitory concentration to reduce cytopathicity by 50% in proliferation of human embryonic lung cells (HEL)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID154154	Cytotoxic concentration for the inhibition of P3HR-1 cell growth	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV.
AID66018	Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-1 (TK-B2006) virus	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.
AID161450	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of rabbit kidney cell morphology	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID85713	Antiviral activity against Herpes Simplex Virus-1 (KOS)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID218050	Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID83024	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID84591	Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID388920	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID675214	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID217983	Compound was evaluated for its antiviral activity against vaccinia	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID88297	Evaluated for minimum inhibitory concentration against G,196, Lyons strains of Herpes simplex virus (HSV-2) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID217995	Antiviral activity against vaccinia virus	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID658756	Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID161456	Antiviral activity against Lyons strain of herpes simplex virus-2 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID224703	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 0	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID86514	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HeLa cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID275086	Antiviral activity against HSV1 KOS in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID246356	Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID1113466	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID260293	Cytotoxicity as determined by alteration in the cell morphology of HEL cells	2006	Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4	Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.
AID1394848	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID611619	Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID280196	Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1113468	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID83328	The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1462032	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID296673	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID1328759	Cytostatic activity against thymidine kinase deficient human HeLa cells after 3 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID161453	Antiviral activity against F strain of herpes simplex virus-1 in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID258990	Antiviral activity against Varicella-Zoster virus 07/1 strain	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID687660	Antiviral activity against Vaccinia virus infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID275074	Antiviral activity against reovirus 1 in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID65707	Antiviral activity against Vaccinia virus in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID220080	Antiviral activity against YS/R strain of thymidine kinase negative(TK-) Varicella-Zoster Virus (VZV)	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82854	Compound was evaluated for the anti-viral activity against HEL cells	1999	Journal of medicinal chemistry, Nov-04, Volume: 42, Issue:22	Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.
AID1854964	Antiviral activity against Human cytomegalovirus AD-169 infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID66941	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID244771	Concentration required to cause a microscopically visible alteration of cell morphology in HEL cells	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID286287	Cytotoxicity against DG75 cells after 120 hrs by MTT assay	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	9-(2-C-Cyano-2-deoxy-beta-D-arabino-pentofuranosyl)guanine, a potential antitumor agent against B-lymphoma infected with Kaposi's sarcoma-associated herpesvirus.
AID81046	In vitro antiviral activity and cytotoxicity, and minimum inhibitory concentration required to reduce cell growth by 50% in HEL cell culture	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID165543	Inhibitory activity against incorporation of deoxy-[methyl.3H-]-thymidine (dThd) into the DNA of uninfected primary rabbit kidney (PRK) cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID63615	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain F induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID64118	Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID216171	Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS(TK+) strain.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID434320	Cytotoxicity against HEL cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID434316	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID304882	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Synthesis and antiviral activity of the carbocyclic analogue of the highly potent and selective anti-VZV bicyclo furano pyrimidines.
AID388918	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.
AID383520	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID216382	Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity in rabbit cell kidney culture	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID296677	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID85719	Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (KOS cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID383524	Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID167138	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (Lycons)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID209372	Compound was tested for antitumor activity against HSV-1 TK gene transformed TK deficient FM3A cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID275089	Cytotoxicity against Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID218251	Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID216472	Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50%	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID228729	Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activity study.
AID83023	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID87144	Tested for cytotoxic activity in human epithelial cell line (HeLa)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID216040	Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID209537	Minimum inhibitory concentration required to reduce TK-VZV (YS/R) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID120301	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 10 mg/kg per day; NT=Not tested	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID482703	Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID675221	Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID1572729	Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID768201	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID217768	Inhibitory dose required to reduce the viability of vero cells by 50%	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID45932	Inhibitory concentration against CMV strain Davis in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID1402825	Antiviral activity against TK-defecient VZV 07-1 infected in HEL cells assessed as reduction in plaque formation after 5 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID81051	Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID87503	Minimum inhibitory concentration required to reduce HSV-1 (F) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID81026	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation.
AID297307	Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID383508	Antiviral activity against Coxsackie virus B4 in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID81205	Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus VZS (OKA) was measured	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID1409613	Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID246524	Concentration required to inhibit human immunodeficiency virus-1 (strain ROD) induced cytopathogenicity in CEM cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID66785	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1328756	Cytostatic activity against human CD4-positive CEM cells after 3 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID1572731	Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID246451	Concentration required to inhibit human cytomegalovirus strain Davis induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID768200	Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID218369	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID284533	Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID1402830	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID90760	50% effective concentration required to reduce cytomegalovirus (CMV AD-169 strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID85119	Effective concentration to show 50% of activity was measured on herpes simplex virus-2 333 strain cell culture.	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID1684813	Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopic analysis	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID257896	Antiviral activity against Sindbis virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1337436	Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor.
AID87508	Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain McIntyre	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID634836	Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID482714	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID63954	Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID1684817	Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID768202	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID161460	Antiviral activity against Vesicular stomatitis virus in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
AID84238	50% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK-) B2006 strain)-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID217485	Minimum inhibitory concentration required to reduce vesicular somatitis virus (VSV (YS)) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID83333	The minimum inhibitory concentration was measured on HEL cells in cell growth	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID64091	Concentration required to inhibit TK-HSV-1 (VMW1837) induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID120294	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 100 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID280186	Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID675212	Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety.
AID87478	Tested for in vitro anti-HSV-1 activity; active	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID88117	Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-2 in PRK cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID246312	Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID66774	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID63746	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (TK- / TK+ HSV-1) strain VMW-1837 induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID218376	Evaluation for antiviral activity against reo virus-1 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID84769	Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (Lyons cells)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID66776	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence 0 ug/mL of 50 ug/mL of 6-aminothymine	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID167136	Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (196)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine].
AID1402823	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction in virus-induced cytopathic effect after 6 to 7 days	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Emimycin and its nucleoside derivatives: Synthesis and antiviral activity.
AID68120	Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(VMW 1837) induced cytopathogenicity in by 50% ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID66782	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID83181	Concentration required to reduce VZV-07/1-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID165528	Concentration required to reduce Vaccinia virus induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.
AID1410509	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Amidate Prodrugs of Cyclic 9-(
AID257892	Antiviral activity against Vesicular stomatitis virus in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1328755	Cytostatic activity against thymidine kinase deficient mouse L1210 cells after 2 days by cell counting method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites.
AID309815	Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).
AID235555	Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration;d ='not determined'.	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID224701	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 6	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID224698	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 12	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID1854962	Antiviral activity against HSV-2 G strain infected in HEL cells assessed as reduction in virus-induced cytopathic effect by microscopic analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.
AID84763	Antiviral activity against Herpes Simplex Virus-2(196)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID1610165	Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID280194	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID87844	Antiviral activity against herpes simplex type-1 expressed as ED90	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID66797	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 300 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID216166	Minimum inhibitory concentration which is active against Varicella zoster virus (VZV); value ranges from 0.0002-0.003 ug/mL	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and antiviral activity of 3'-deoxy-3'-C-hydroxymethyl nucleosides.
AID217975	50% effective concentration required to reduce vaccinia virus-induced cytopathicity	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues.
AID297310	Cytotoxicity against human HEL cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID30872	Antiherpes activity was tested as percent of control of plaque-formation against ACG (S1) virus by 30 uM of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID768203	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID288915	Cytotoxicity against E6SM cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID217998	Evaluated for minimum inhibitory concentration against Vaccinia virus (VV) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID41208	The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BALB/3T3 cell line	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID217890	Evaluated for minimum inhibitory concentration against Vero cells (African green monkey) infected with PV-3, RV-1, SV, Coxs B4, SFV virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID539916	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID303231	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID63625	Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-2) strain Lyons induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID87504	Minimum inhibitory concentration required to reduce HSV-1 (KOS) strain-induced cytopathogenicity in primary rabbit kidney cell cultures	1981	Journal of medicinal chemistry, Jun, Volume: 24, Issue:6	Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2'-deoxyuridine.
AID1457766	Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1427828	Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition
AID553340	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID634837	Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1498114	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID224691	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 0	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID216156	Effective concentration against TK- Varicella-Zoster Virus (VZV) YS/R strain	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID66940	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID81193	Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID64093	Concentration required to inhibit VSV induced cytopathogenicity in E6SM cells by 50%.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID768205	Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID72048	Compound was tested for antitumor activity against FM3A/TK- cells	1987	Journal of medicinal chemistry, Aug, Volume: 30, Issue:8	Synthesis and biological activity of 5-(2,2-difluorovinyl)-2'-deoxyuridine.
AID216154	Effective concentration against TK+ Varicella-Zoster Virus (VZV)YS strain	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID66768	The compound was tested for its antiviral activity against HSV-2 (G) virus in E6SM cell culture	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID83199	Minimum inhibitory concentration required for antiviral activity to reduce Varicella Zoster virus (VZV) (Oka) induced cytopathicity in human embryonic lung cells (HEL)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID1422439	Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID235593	Ratio of ID50/ID90 in HSV-1 infected cells	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.
AID63754	Tested for the minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%.	1995	Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5	Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.
AID383528	Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID634752	Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID383506	Cytotoxicity against human HeLa cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID224706	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 3	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID246561	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID218249	Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID297311	Cytotoxicity against human HEL cells assessed as reduction of cell growth	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID45815	The mitochondrial toxicity was measured on human T-lymphoid CEM cells.	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID1230100	Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID280175	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID383512	Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID209531	Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (VMW 1837) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID634758	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID607914	Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides.
AID539919	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID83193	Minimum inhibitory conc. for 50% inhibition of VZV (OKA) virus plaque formation in HEL cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID106003	Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides.
AID303228	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID246415	Concentration required to inhibit herpes simplex virus type 2 induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID658754	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID232771	Selectivity index against HSV-2 was determined as CD50/ED50 ratio	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	S-glucosylated hydantoins as new antiviral agents.
AID87146	Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID303237	Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID434309	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID85558	Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues.
AID120305	In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 5 mg/kg per day	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID125368	Inhibitory activity against Molt/4F cell line	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives.
AID383513	Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID64107	Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (196) was measured.	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines.
AID27595	Partition coefficient (logP)	2002	Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23	CycloSal-BVDUMP pronucleotides: how to convert an antiviral-inactive nucleoside analogue into a bioactive compound against EBV.
AID224705	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 20	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID687666	Cytotoxicity against HEL assessed as minimum compound concentration causes microscopically detectable alteration of cell morphology after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID1294505	Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID464182	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID63596	Minimum inhibitory conc. for 50% inhibition of HSV-2 (G) virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID296674	Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID83204	Tested for antiviral activity against thymidine kinase deficient Varicella zoster virus in human embryonic lung fibroblasts	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID84605	Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID68254	Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID246259	Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	6-azapyrimidine-2'-deoxy-4'-thionucleosides: antiviral agents against TK+ and TK- HSV and VZV strains.
AID65711	Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID611618	Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1782672	Antiviral activity against thymidine kinase positive Varicella zoster virus	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID1294504	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
AID482713	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1727354	Cytotoxicity against human HEL cells assessed as concentration required to cause visible alteration in cell morphology incubated for 3 days by coulter counter method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Extension of furopyrimidine nucleosides with 5-alkynyl substituent: Synthesis, high fluorescence, and antiviral effect in the absence of free ribose hydroxyl groups.
AID166985	Minimum cytotoxic concentration causing microscopically detectable alteration of normal cell morphology of rabbit kidney cells	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds.
AID63600	Minimum inhibitory conc. for 50% inhibition of vaccinia virus induced cytopathicity in E6SM cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID218518	Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	S-glucosylated hydantoins as new antiviral agents.
AID434318	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID63759	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID275088	Cytotoxicity against HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID326136	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID246474	Concentration required to inhibit Varicella-Zoster virus (strain 07/1) induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID224708	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 9	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID217670	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID217673	Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID83196	Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (AD-169) induced cytopathicity in human embryonic lung cells (HEL)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID611620	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID84933	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%	2001	Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21	Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides.
AID297306	Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID1457767	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka strain assessed as inhibition of plaque formation	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID81040	Minimum cytotoxic concentration against HEL cell morphology.	2002	Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19	Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles.
AID217496	The effective concentration to show 50% of activity was measured on varicella zoster virus(Ellen) cell culture	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses.
AID216350	Tested for antiviral activity against parainfluenza virus in african green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID63758	The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID218252	Evaluation for antiviral activity against forest virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID288920	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1394844	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in HEL cells assessed as inhibition of plaque formation measured after 5 days post infection	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates.
AID218253	Evaluation for antiviral activity against Sindbis virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1382170	Selectivity index, ratio of CC50 for HEL cells to EC50 for thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID83497	Inhibition of cell proliferation expressed as CC50	1998	Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25	Synthesis of imidazo[1,2-a]pyridines as antiviral agents.
AID210687	Catalytic turnover constant of compound against HSV-1 thymidine kinase; ND denotes not determined	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID63953	Concentration required to cause a microscopically detectable alteration of normal cell morphology in E6SM cells	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
AID687665	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	2012	European journal of medicinal chemistry, Nov, Volume: 57	Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides.
AID246409	Concentration required to inhibit vesicular stomatitis virus induced cytopathogenicity in HEL cells by 50%	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
AID1684814	Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation measured on 6 to 7 post-viral infection	2021	ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1	Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID387582	Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID228732	Minimum cytotoxic concentration that causes microscopically detectable alterations of cell morphology	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID553341	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates.
AID419595	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID209536	Minimum inhibitory concentration required to reduce TK-VZV (07-1) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID1382165	Antiviral activity against Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID1462035	Antiviral activity against wild type thymidine kinase-deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus-induced plaque formation	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
AID1382172	Antiviral activity against thymidine kinase deficient acyclovir-resistant Human simplex virus 1 KOS infected in HEL cells assessed as reduction in viral cytopathic effect	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates.
AID419593	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID326137	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID284525	Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID383511	Cytotoxicity against human HEL cells assessed as alteration of cell morphology	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID297318	Antiviral activity against Reovirus 1 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID86215	Antiviral activity against HSV-1 (Brand) in human epithelial (Hep-2) cells	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID1572733	Antiviral activity against Varicella-zoster virus Oka harboring thymidine kinase infected in HEL cells assessed as reduction in virus plaque formation	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID419594	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID217490	Minimum inhibitory concentration required to reduce vaccinia virus (VV) virus-induced cytopathicity by 50%	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID1427832	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
AID1409611	AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID392536	Antiviral activity against Vaccinia virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID87456	Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in HeLa	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID665389	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines.
AID66796	The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 30 ug/mL dThd	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID296676	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core.
AID216170	Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using OKA (TK+) strain	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID224700	Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 3	1993	Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues.
AID217651	Minimum inhibitory concentration was determined against VZV (TK-07/1) in HEL cells	2000	Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4	The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
AID66021	Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against Varicella-Zoster virus (YS)	1998	Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22	5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.
AID280177	Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID611616	Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1498116	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID665384	Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2'-deoxyuridines.
AID291035	Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID85380	Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture	1993	Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14	Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides.
AID257900	Antiviral activity against Coxsackie virus B4 in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID432173	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1361086	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka infected in human HEL cells assessed as reduction in plaque formation after 5 days	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation.
AID217665	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.
AID217901	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against measles virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1869610	Antiviral activity against HCMV AD-169 infected in HEL cells assessed as reduction in virus plaque formation	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.
AID482706	Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID258993	Antiviral activity against human cytomegalovirus Davis strain	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	226 (45.29)	18.7374
1990's	85 (17.03)	18.2507
2000's	105 (21.04)	29.6817
2010's	72 (14.43)	24.3611
2020's	11 (2.20)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	17 (3.30%)	5.53%
Reviews	38 (7.38%)	6.00%
Case Studies	29 (5.63%)	4.05%
Observational	0 (0.00%)	0.25%
Other	431 (83.69%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers [NCT00031616]			Phase 1/Phase 2	0 participants	Interventional	2001-12-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.03	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetamide acetimidic acid : A carboximidic acid that is acetic acid in which the carbonyl oxygen is replaced by an imino group.	2.03	1	0	acetamides; carboximidic acid; monocarboxylic acid amide; N-acylammonia
adenine [no description available]	4.32	6	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.03	1	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
catechol [no description available]	2.03	1	0	catechols	allelochemical; genotoxin; plant metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	2.06	1	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
taxifolin [no description available]	2.03	1	0	3'-hydroxyflavanones; 4'-hydroxyflavanones; dihydroflavonols; pentahydroxyflavanone; secondary alpha-hydroxy ketone
phosphonoacetic acid Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.	7.49	24	1	monocarboxylic acid; phosphonic acids	antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	2.03	1	0	catechols; dihydroxyphenylacetic acid	human metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.03	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
fosmidomycin fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source. fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.	2.06	1	0	hydroxamic acid; phosphonic acids	antimicrobial agent; bacterial metabolite; EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
cytosine [no description available]	5.74	11	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
diacetyl butane-2,3-dione : An alpha-diketone that is butane substituted by oxo groups at positions 2 and 3. It is a metabolite produced during the malolactic fermentation.	2.03	1	0	alpha-diketone	Escherichia coli metabolite; Saccharomyces cerevisiae metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.37	2	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
hydroquinone [no description available]	2.03	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
melatonin [no description available]	2.03	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
n-acetylserotonin N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid.	2.03	1	0	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist
4-aminobenzoic acid 4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.	1.99	1	0	aminobenzoic acid; aromatic amino-acid zwitterion	allergen; Escherichia coli metabolite; plant metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	2.03	1	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
quinolinic acid Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.	2.03	1	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
taurine [no description available]	2.03	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
thymine [no description available]	2.66	3	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2.89	4	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2.03	1	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
alpha-methyl-4-carboxyphenylglycine [no description available]	2.03	1	0
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist	2.03	1	0
1-hydroxy-3-amino-2-pyrrolidone 1-hydroxy-3-amino-2-pyrrolidone: a CNS depressant; structure in first source	2.03	1	0
ibotenic acid Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.	2.03	1	0	non-proteinogenic alpha-amino acid	neurotoxin
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane N(8)-bromoacetyl-N(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane: structure given in first source	2.03	1	0
sk&f-38393 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.. 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.. SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393	2.03	1	0	benzazepine; catechols; secondary amino compound
vanilmandelic acid Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.. vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.	2.03	1	0	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite
1,10-diaminodecane [no description available]	2.03	1	0
1,3-diethyl-8-phenylxanthine 1,3-diethyl-8-phenylxanthine: structure given in first source	2.03	1	0
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	2.03	1	0	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1,3-dipropyl-8-(4-sulfophenyl)xanthine 1,3-dipropyl-8-(4-sulfophenyl)xanthine: adenosine receptor antagonist	2.03	1	0
1,5-dihydroxyisoquinoline 1,5-dihydroxyisoquinoline: structure in first source. isoquinoline-1,5-diol : An isoquinolinol that is isoquinoline in which the hydrogens at positions 1 and 5 are replaced by hydroxy groups.	2.03	1	0	isoquinolinol	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.03	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-(2-trifluoromethylphenyl)imidazole 1-(2-trifluoromethylphenyl)imidazole: an inhibitor of neuronal nitric oxide synthase in mouse	2.03	1	0	imidazoles
1-aminobenzotriazole [no description available]	2.03	1	0
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.01	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
1-methylimidazole 1-methyl-1H-imidazole : A 1H-imidazole having a methyl substituent at the N-1 position.	2.03	1	0	imidazoles
edelfosine edelfosine: RN given refers to parent cpd. edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.. 1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.	2.03	1	0	glycerophosphocholine
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.	2.03	1	0	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor
2,2'-dipyridyl 2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.	2.03	1	0	bipyridine	chelator; ferroptosis inhibitor
2-hydroxysaclofen 2-hydroxysaclofen: structure given in first source	2.03	1	0	organochlorine compound
3,4-dichloroisocoumarin 3,4-dichloroisocoumarin : A member of the class of isocoumarins that is isocoumarin substituted by chloro groups at positions 3 and 4. It is a serine protease inhibitor.	2.03	1	0	isocoumarins; organochlorine compound	geroprotector; serine protease inhibitor
phaclofen phaclofen: peripheral & central baclofen & GABA antagonist; structure given in first source	2.03	1	0	organophosphate oxoanion; zwitterion
3-aminobenzamide [no description available]	2.03	1	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-bromo-7-nitroindazole [no description available]	2.03	1	0
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.03	1	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.03	1	0	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
4-amino-1,8-naphthalimide 4-amino-1,8-naphthalimide: inhibits ADP-ribosylation; sometimes abreviated as 4-AN;	2.03	1	0	benzoisoquinoline; dicarboximide
4-aminopyridine [no description available]	2.03	1	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.	2.03	1	0	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
4-hydroxybenzoic acid hydrazide 4-hydroxybenzoic acid hydrazide: metabolite of nifuroxazide. 4-hydroxybenzohydrazide : A carbohydrazide obtained by formal condensation of the carboxy group of 4-hydroxybenzoic acid with hydrazine.	2.03	1	0	carbohydrazide; phenols
4-phenyl-3-furoxancarbonitrile 4-phenyl-3-furoxancarbonitrile: structure given in first source. 4-phenyl-3-furoxancarbonitrile : A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation.	2.03	1	0	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
5,5-dimethyl-1-pyrroline-1-oxide 5,5-dimethyl-1-pyrroline-1-oxide: do not confuse with DMPO (4',5'-dihydroxy-7-methoxy-4-phenyl-5,2'-oxidocoumarin). 5,5-dimethyl-1-pyrroline N-oxide : A member of the class of 1-pyrroline nitrones (1-pyrroline N-oxides) resulting from the formal N-oxidation of 5,5-dimethyl-1-pyrroline. Used as a spin trap for the study of radicals formed by enzymatic acetaldehyde oxidation.	2.03	1	0	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent
phenytoin [no description available]	2.03	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
5,7-dichlorokynurenic acid 5,7-dichlorokynurenic acid: potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site	2.03	1	0	quinolines
5-(n,n-hexamethylene)amiloride 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity. 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.	2.03	1	0	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
ethylisopropylamiloride ethylisopropylamiloride: structure in first source. ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.	2.03	1	0	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
5-fluoroindole-2-carboxylic acid 5-fluoroindole-2-carboxylic acid: N-methyl-D-aspartate receptor antagonist	2.03	1	0	indolyl carboxylic acid
hydroxyindoleacetic acid (5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.	2.03	1	0	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
phenanthridone phenanthridone: coal tar derivative; structure given in first source. phenanthridone : A member of the class of phenanthridines that is phenanthridine with an oxo substituent at position 6. A poly(ADP-ribose) polymerase (PARP) inhibitor, it has been shown to exhibit immunosuppressive activity.	2.03	1	0	lactam; phenanthridines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; immunosuppressive agent; mutagen
6-chloromelatonin [no description available]	2.03	1	0	acetamides
6-hydroxymelatonin 6-hydroxymelatonin : A member of the class of tryptamines that is melatonin with a hydroxy group substituent at position 6.	2.03	1	0	acetamides; tryptamines	metabolite; mouse metabolite
6-methoxytryptoline 6-methoxytryptoline: RN given refers to parent cpd; structure	2.03	1	0
6-nitroso-1,2-benzopyrone [no description available]	2.03	1	0
7-chlorokynurenic acid 7-chlorokynurenic acid: selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex; structure given in first source. 7-chlorokynurenic acid : A quinolinemonocarboxylic acid that is quinaldic acid which is substituted by a hydroxy group at position 4 and by a chlorine at position 7. It is a potent NMDA glutamate receptor antagonist which antagonizes the strychnine-insensitive glycine site of the NMDA receptor. It also prevents neurodegeneration produced by quinolinic acid.	2.03	1	0	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist
7-nitroindazole 7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure	2.03	1	0
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	2.03	1	0
8-cyclopentyl-1,3-dimethylxanthine 8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats	2.03	1	0	oxopurine
8-phenyltheophylline 8-phenyltheophylline: purinergic P1 receptor antagonist	2.03	1	0
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.06	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.06	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.03	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.	2.03	1	0	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
ag 127 tyrphostin AG 126: inhibits development of postoperative ileus induced by surgical manipulation of murine colon	2.03	1	0	nitrophenol
rtki cpd [no description available]	2.03	1	0	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
tyrphostin a23 tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source	2.03	1	0	catechols
tyrphostin 25 [no description available]	2.03	1	0	benzenetriol
tyrphostin a1 [no description available]	2.03	1	0	methoxybenzenes	geroprotector
1-aminoindan-1,5-dicarboxylic acid 1-aminoindan-1,5-dicarboxylic acid: structure given in first source	2.03	1	0
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.03	1	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alpha-methyltyrosine methyl ester alpha-methyltyrosine methyl ester: RN given refers to parent cpd	2.03	1	0
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.06	1	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	2.03	1	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	7.16	16	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
amfonelic acid amfonelic acid: CNS-stimulant	2.03	1	0
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	2.03	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
theophylline [no description available]	2.03	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.03	1	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
aniracetam [no description available]	2.03	1	0	N-acylpyrrolidine; pyrrolidin-2-ones
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	1.99	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.06	1	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
2-amino-4-phosphonobutyric acid 2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version	2.03	1	0
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.45	2	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	4.04	2	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.45	2	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate: a glutamate agonist	2.03	1	0	alpha-amino acid
aurintricarboxylic acid Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.	2.03	1	0	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.03	1	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelaic acid nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.	2.03	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite
baclofen [no description available]	2.03	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bay-k-8644 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.	2.03	1	0	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
benserazide Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.	2.06	1	0	carbohydrazide; catechols; primary alcohol; primary amino compound	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.03	1	0	benzamides
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.06	1	0	1-benzofurans; aromatic ketone	uricosuric drug
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.03	1	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
betaxolol [no description available]	2.06	1	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bml 190 indomethacin morpholinylamide: an inverse agonist of the cannabinoid CB2 receptor	2.03	1	0	N-acylindole
brimonidine [no description available]	2.03	1	0	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.06	1	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bumetanide [no description available]	2.03	1	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
caffeine [no description available]	2.45	2	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
camostat camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.	4.04	2	0	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.03	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbetapentane carbetapentane: RN given refers to parent cpd	4.2	3	0	benzenes
carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.	2.03	1	0	carbamate ester	muscle relaxant
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.03	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
cgs 12066 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline : A pyrroloquinoxaline that is pyrrolo[1,2-a]quinoxaline bearing additional 4-methylpiperazin-1-yl and trifluoromethyl substituents at positions 4 and 7 respectively. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration.	2.03	1	0	N-arylpiperazine; organofluorine compound; pyrroloquinoxaline	serotonergic agonist
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	2.03	1	0	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.03	1	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlormezanone Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.	2.03	1	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	4.43	4	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	2.45	2	0	benzothiadiazine	antihypertensive agent; diuretic
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.03	1	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.03	1	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cilostamide cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure	2.03	1	0	quinolines
cilostazol [no description available]	2.03	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.03	1	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cinoxacin Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.	2.03	1	0	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
ciprofibrate [no description available]	2.03	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.45	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	2.21	1	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
cloperastine cloperastine: RN given refers to parent cpd	4.04	2	0	diarylmethane
clotrimazole [no description available]	2.03	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cromolyn cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.	2.06	1	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
cx546 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source	2.03	1	0
cyclothiazide cyclothiazide: inhibits the desensitization of AMPA-type receptors; structure. cyclothiazide : 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema.	2.03	1	0	benzothiadiazine	antihypertensive agent; diuretic
dephostatin dephostatin: from Streptomyces sp. MJ742-NF5; structure given in first source	2.03	1	0
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.06	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
nonivamide nonivamide: has effect on sensory neurons. nonivamide : A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.	2.03	1	0	capsaicinoid; phenols	lachrymator
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.06	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	2.03	1	0	diarylmethane
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.03	1	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.06	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	2.03	1	0	pentacarboxylic acid	copper chelator
diphenyleneiodonium diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor. dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.	2.03	1	0	organic cation
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.45	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	2.03	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	2.45	2	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	4.04	2	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
2-amino-7-phosphonoheptanoic acid 2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation	2.03	1	0
thiorphan Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.	2.03	1	0	N-acyl-amino acid
2,3-dimethoxy-1,4-naphthoquinone 2,3-dimethoxynaphthalene-1,4-dione : A naphthoquinone that is 1,4-naphthoquinone bearing two methoxy substituents at positions 2 and 3. Redox-cycling agent that induces intracellular superoxide anion formation and, depending on the concentration, induces cell proliferation, apoptosis or necrosis. Used to study the role of ROS in cell toxicity, apoptosis, and necrosis.	2.03	1	0	1,4-naphthoquinones
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.03	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	2.03	1	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.03	1	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.03	1	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	2.03	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.03	1	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	2.45	2	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	10.48	15	2	2-aminopurines; acetate ester	antiviral drug; prodrug
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	2.45	2	0	carbamate ester	anticonvulsant; neuroprotective agent
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.03	1	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.03	1	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.06	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.76	3	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	1.99	1	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.03	1	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	11	21	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluspirilene Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.	2.03	1	0	diarylmethane
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.03	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
formoterol fumarate N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide : A phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent.	2.03	1	0	formamides; phenols; phenylethanolamines; secondary alcohol; secondary amino compound
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	11.64	29	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
fpl 64176 FPL 64176: an activator of L-type calcium channels; structure given in first source. FPL 64176 : 1H-Pyrrole substituted at C-2 and -5 by methyl groups, at C-3 by methoxycarbonyl and at C-4 by a 2-benzylbenzoyl group.	2.03	1	0	carboxylic ester; pyrroles	calcium channel agonist
furafylline [no description available]	2.03	1	0	oxopurine
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.45	2	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
fusaric acid Fusaric Acid: A picolinic acid derivative isolated from various Fusarium species. It has been proposed for a variety of therapeutic applications but is primarily used as a research tool. Its mechanisms of action are poorly understood. It probably inhibits DOPAMINE BETA-HYDROXYLASE, the enzyme that converts dopamine to norepinephrine. It may also have other actions, including the inhibition of cell proliferation and DNA synthesis.	2.03	1	0	aromatic carboxylic acid; pyridines
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	2.03	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
4-amino-5-hexynoic acid 4-amino-5-hexynoic acid: structure	2.03	1	0
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.03	1	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.03	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
1-(5-isoquinolinesulfonyl)piperazine [no description available]	2.03	1	0	isoquinolines
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	4.2	3	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hemicholinium 3 [no description available]	2.03	1	0	morpholines
4-fluorohexahydrosiladifenidol [no description available]	2.03	1	0
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.45	2	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	4.35	3	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	2.42	2	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
ibudilast [no description available]	2.03	1	0	pyrazolopyridine
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.45	2	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
ic 261 [no description available]	2.03	1	0	indoles
ifenprodil ifenprodil: NMDA receptor antagonist	4.2	3	0	piperidines
ifosfamide [no description available]	2.01	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.03	1	0
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	4.41	4	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoacetamide [no description available]	2.03	1	0
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.06	1	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.06	1	0	organic molecular entity
iotroxic acid iotroxic acid: RN given refers to parent cpd; structure	2.06	1	0	organic molecular entity
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	2.03	1	0	3-isobutyl-1-methylxanthine
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	2.06	1	0	benzenes
4-piperidinecarboxylic acid 4-piperidinecarboxylic acid: structure in first source	2.03	1	0
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline WHI P131: a quinazoline derivative, inhibitor of glioblastoma cell adhesion and migration	2.03	1	0
jl 18 JL 18: a pyridobenzodiazepine derivative bioisoster of clozapine	2.03	1	0
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.03	1	0	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.03	1	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.45	2	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	2.06	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	2.03	1	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid 2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3. 2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group.	2.03	1	0	alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids	human metabolite; metabotropic glutamate receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.06	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	2.03	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.45	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.03	1	0	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.03	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
linopirdine linopirdine: acetylcholine releasing drug	2.03	1	0	indoles
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	4.2	3	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
loxoprofen loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source. loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.	2.03	1	0	cyclopentanones; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.03	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
meclofenamate sodium anhydrous [no description available]	2.03	1	0	organic sodium salt
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	2.06	1	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	4.23	3	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methiothepin Methiothepin: A serotonin receptor antagonist in the CENTRAL NERVOUS SYSTEM used as an antipsychotic.. methiothepin : A dibenzothiepine that is 10,11-dihydrodibenzo[b,f]thiepine bearing additional methylthio and 4-methylpiperazin-1-yl substituents at positions 8 and 10 respectively. Potent 5-HT2 antagonist, also active as 5-HT1 antagonist. Differentiates 5-HT1D sub-types. Also displays affinity for rodent 5-HT5B, 5-HT5A, 5-HT7 and 5-HT6 receptors (pK1 values are 6.6, 7.0, 8.4 and 8.7 respectively).	2.03	1	0	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
methoctramine [no description available]	2.03	1	0	aromatic ether; tetramine	muscarinic antagonist
nocodazole [no description available]	2.03	1	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
3-Hydroxy-alpha-methyl-DL-tyrosine [no description available]	2.03	1	0	benzenes; monocarboxylic acid
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	2.45	2	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.06	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
milrinone [no description available]	2.03	1	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	4.41	4	0	dialkylarylamine; tertiary amino compound
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	2.03	1	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.73	3	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
ml 7 ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).	2.03	1	0	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	2.06	1	0	monoterpenoid
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide: calmodulin antagonist; structure given in first source. N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide : A sulfonamide that is 5-chloronaphthalene-2-sulfonamide in which one of the hydrogens of the nitrogen atom is substituted by a 4-aminobutyl group.	2.03	1	0	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
n-bromoacetamide [no description available]	2.03	1	0
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.03	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
fg 7142 FG 7142: benzodiazepine receptor agonist	2.03	1	0	beta-carbolines
fenamic acid fenamic acid: has chloride and potassium channel-blocking activity; RN given refers to parent cpd. fenamic acid : An aminobenzoic acid that is the N-phenyl derivative of anthranilic acid. It acts as a parent skeleton for the synthesis of several non-steroidal anti-inflammatory drugs.	2.03	1	0	aminobenzoic acid; secondary amino compound	membrane transport modulator
n 0840 N(6)-cyclopentyl-9-methyladenine: selective, orally active A(1) adenosine receptor antagonist	2.03	1	0
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	4.04	2	0	benzoic acids; guanidines
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.74	3	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent.	2.03	1	0	organonitrogen compound; organooxygen compound
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.03	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.03	1	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
niflumic acid Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.	2.03	1	0	aromatic carboxylic acid; pyridines
nilutamide [no description available]	2.03	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.03	1	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.03	1	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nipecotic acid nipecotic acid: RN given refers to cpd without isomeric designation. nipecotic acid : A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group.	2.03	1	0	beta-amino acid; piperidinemonocarboxylic acid
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.45	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.03	1	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.05	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
5-nitro-2-(3-phenylpropylamino)benzoic acid 5-nitro-2-(3-phenylpropylamino)benzoic acid: structure given in first source; chloride channel antagonist	2.03	1	0	nitrobenzoic acid
ns 2028 NS 2028: structure in first source	2.03	1	0
ns 1619 NS 1619: structure given in first source. NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).	2.03	1	0	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener
o(6)-benzylguanine O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity	2.03	1	0
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.46	2	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.44	2	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	2.03	1	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxatomide oxatomide: structure; an anti-allergic & an anti-asthmatic. oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.	2.03	1	0	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
oxiracetam oxiracetam: structure in first source	2.03	1	0	organonitrogen compound; organooxygen compound
oxolinic acid quinolone antibiotic : An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.	2.03	1	0	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).	2.03	1	0	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
fenclonine Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.	2.03	1	0	phenylalanine derivative
palmidrol palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.	2.03	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
pamidronate [no description available]	2.06	1	0	phosphonoacetic acid
1,7-dimethylxanthine 1,7-dimethylxanthine : A dimethylxanthine having the two methyl groups located at positions 1 and 7. It is a metabolite of caffeine and theobromine in animals.	2.03	1	0	dimethylxanthine	central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.03	1	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.45	2	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentoxifylline [no description available]	2.03	1	0	oxopurine
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.03	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenyl biguanide phenyl biguanide: RN given refers to parent cpd. phenyl biguanide : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a phenyl group.	2.03	1	0	guanidines	central nervous system drug
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.03	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
phloretin [no description available]	2.03	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
phthalylsulfathiazole phthalylsulfathiazole: minor descriptor (63-86); on-line & INDEX MEDICUS search SULFATHIAZOLES (66-86); RN given refers to parent cpd. phthalylsulfathiazole : A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.	2.06	1	0	1,3-thiazoles; dicarboxylic acid monoamide; sulfonamide antibiotic; sulfonamide
moxonidine moxonidine: structure given in first source	2.06	1	0	organohalogen compound; pyrimidines
picotamide picotamide: has anticoagulant & fibrinolytic properties; structure	2.03	1	0	benzamides
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.03	1	0	pyridines
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	2.03	1	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	4.04	2	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piperidine-4-sulfonic acid piperidine-4-sulfonic acid: specific GABA agonist	2.03	1	0
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.03	1	0	organonitrogen compound; organooxygen compound
pirbuterol pirbuterol: structure	2.06	1	0	pyridines
pirenperone [no description available]	2.03	1	0	aromatic ketone
praziquantel azinox: Russian drug	2.03	1	0	isoquinolines
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	2.03	1	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
proglumide Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.. proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.. N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.	2.03	1	0	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
propentofylline [no description available]	2.03	1	0	oxopurine
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.03	1	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.06	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
quetiapine [no description available]	2.06	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
ranitidine [no description available]	2.06	1	0	aralkylamine
pf 5901 alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist	2.03	1	0	quinolines
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.03	1	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	5.02	12	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.03	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
ritanserin Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.	2.03	1	0	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.	2.03	1	0	methoxybenzenes
rolipram [no description available]	2.03	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.06	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
salmeterol xinafoate salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.. 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.	2.03	1	0	ether; phenols; primary alcohol; secondary alcohol; secondary amino compound
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.03	1	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sobuzoxane sobuzoxane: used in treatment of leukemia L1210	2.03	1	0	organic molecular entity
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.06	1	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.06	1	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
spiroxatrine spiroxatrine: structure	2.03	1	0	imidazolidines
sq 22536 9-(tetrahydrofuryl)adenine : A nucleoside analogue that is adenine in which the nitrogen at position 9 has been substituted by a tetrahydrofuran-2-yl group. It is an adenylate cyclase inhibitor.	2.03	1	0	nucleoside analogue; oxolanes	EC 4.6.1.1 (adenylate cyclase) inhibitor
succinylsulfathiazole succinylsulfathiazole: intestinal antimicrobial agent; structure	2.06	1	0	1,3-thiazoles
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.03	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.45	2	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sultopride [no description available]	2.06	1	0	salicylamides
t0156 [no description available]	2.03	1	0	naphthyridine derivative
1,4-bis(2-(3,5-dichloropyridyloxy))benzene 1,4-bis(2-(3,5-dichloropyridyloxy))benzene: potent phenobarbital-like inducer of microsomal monooxygenase activity; structure given in first source	2.03	1	0
tegafur [no description available]	2.37	2	0	organohalogen compound; pyrimidines
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.06	1	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.03	1	0	diarylmethane
tetraisopropylpyrophosphamide Tetraisopropylpyrophosphamide: N,N',N'',N'''-Tetraisopropylpyrophosphamide. A specific inhibitor of pseudocholinesterases. It is commonly used experimentally to determine whether pseudo- or acetylcholinesterases are involved in an enzymatic process.	2.03	1	0	phosphoramide
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.03	1	0	phthalimides; piperidones
theobromine Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9). theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.	2.03	1	0	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate: intracellular calcium antagonist; RN given refers to parent cpd	2.03	1	0	trihydroxybenzoic acid
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	2.03	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.45	2	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid: a GABA-C receptor antagonist; structure in first source	2.03	1	0
ici 136,753 [no description available]	2.03	1	0	pyrazolopyridine
trapidil Trapidil: A coronary vasodilator agent.	2.06	1	0	triazolopyrimidines
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.03	1	0	pteridines	diuretic; sodium channel blocker
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.45	2	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
tropicamide Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.	2.03	1	0	acetamides
tyrphostin a9 [no description available]	2.03	1	0	alkylbenzene	geroprotector
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.05	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
urapidil [no description available]	2.06	1	0	piperazines
vigabatrin [no description available]	2.03	1	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: adenosine receptor antagonist	2.03	1	0
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.	2.03	1	0	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zardaverine zardaverine: structure given in first source. zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.	2.03	1	0	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
cortisone acetate Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.	2.03	1	0	corticosteroid hormone
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.01	1	0	mitomycin	alkylating agent; antineoplastic agent
corticosterone [no description available]	2.03	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.03	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
thymidine [no description available]	7.22	41	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	3.85	12	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
procaine hydrochloride Gerovital H3: Contains mainly procaine & small amounts of benzoic acid, potassium metabisulfite & disodium phosphate	2.03	1	0	organic molecular entity
triethylenemelamine Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.	1.99	1	0	1,3,5-triazines	alkylating agent; insect sterilant
bromouracil Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.	3.35	7	0	nucleobase analogue; pyrimidines	mutagen
isoproterenol hydrochloride [no description available]	2.03	1	0	catechols
histamine dihydrochloride Ceplene: Tradename for histamine dihydrochloride.	2.03	1	0
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	2.03	1	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	2.03	1	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2.03	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
androsterone [no description available]	2.03	1	0	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid	androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone
promazine hydrochloride [no description available]	2.03	1	0	hydrochloride
idoxuridine [no description available]	9.39	63	1	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
pilocarpine hydrochloride pilocarpine hydrochloride : The hydrochloride salt of (+)-pilocarpine, a medication used to treat increased pressure inside the eye and dry mouth.	2.03	1	0	hydrochloride
dimethylphenylpiperazinium iodide Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.	2.03	1	0	N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt	nicotinic acetylcholine receptor agonist
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.03	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
racepinephrine hydrochloride [no description available]	2.03	1	0
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes.	2.03	1	0
hexamethonium bromide [no description available]	2.03	1	0
cystamine dihydrochloride [no description available]	2.03	1	0
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	2.03	1	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
tetraethylammonium chloride tetraethylammonium chloride : A quarternary ammonium chloride salt in which the cation has four ethyl substituents around the central nitrogen.	2.03	1	0	organic chloride salt; quaternary ammonium salt	potassium channel blocker
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	5.58	4	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.03	1	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2.03	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	1.96	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
vincristine [no description available]	2.03	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	2.03	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.03	1	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.06	1	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
promethazine hydrochloride [no description available]	2.03	1	0	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.04	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
uridine [no description available]	3.57	9	0	uridines	drug metabolite; fundamental metabolite; human metabolite
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.06	1	0	kanamycins	bacterial metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	16.96	367	15	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.03	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.06	1	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
methoxamine hydrochloride [no description available]	2.03	1	0	dimethoxybenzene
papaverine hydrochloride [no description available]	2.03	1	0
bretylium tosylate Bretylium Tosylate: An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.. bretylium tosylate : The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.03	1	0	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
berlition berlition: antioxidant preparation containing alpha-lipoic acid, used in the neuroprotective therapy of chronic brain ischemia for correction of free-radical processes. (R)-lipoic acid : The (R)-enantiomer of lipoic acid. A vitamin-like, C8 thia fatty acid with anti-oxidant properties.. lipoic acid : A heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position.	2.03	1	0	dithiolanes; heterocyclic fatty acid; lipoic acid; thia fatty acid	cofactor; nutraceutical; prosthetic group
methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)	2.03	1	0	quaternary ammonium salt
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	2.03	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	1.96	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.03	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
yohimbine hydrochloride [no description available]	2.03	1	0
gallamine triethiodide Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)	2.03	1	0
cytidine triphosphate Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.68	3	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.03	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	2.03	1	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	2.45	2	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
17-alpha-hydroxyprogesterone 17alpha-hydroxyprogesterone : A 17alpha-hydroxy steroid that is the 17alpha-hydroxy derivative of progesterone.	2.03	1	0	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin
quinacrine monohydrochloride [no description available]	2.03	1	0
chlorpromazine hydrochloride [no description available]	2.03	1	0	hydrochloride; phenothiazines	anticoronaviral agent; phenothiazine antipsychotic drug
mannitol [no description available]	2.06	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine hydrochloride [no description available]	2.03	1	0
cytarabine [no description available]	6.57	21	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	7.9	24	3	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	9.42	11	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.03	1	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
lidocaine hydrochloride lidocaine hydrochloride : The anhydrous form of the hydrochloride salt of lidocaine.	2.03	1	0	hydrochloride	anti-arrhythmia drug; local anaesthetic
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.45	2	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.08	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.03	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
synephrine [no description available]	2.03	1	0	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite
pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.	2.03	1	0	pyridinium salt
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.68	3	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
imipramine hydrochloride [no description available]	2.03	1	0	hydrochloride	antidepressant
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.03	1	0	bromide salt
edrophonium chloride edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	2.03	1	0	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.06	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
suramin sodium suramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.	2.03	1	0	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.03	1	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
fluorodeoxyuridylate Fluorodeoxyuridylate: 5-Fluoro-2'-deoxyuridylate. An inhibitor of thymidylate synthetase. Formed from 5-fluorouracil or 5-fluorodeoxyuridine.	2.65	3	0	pyrimidine 2'-deoxyribonucleoside 5'-monophosphate
methapyrilene hydrochloride methapyrilene hydrochloride : A hydrochloride that is the monohydrochloride salt of methapyrilene.	2.03	1	0	hydrochloride	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
tetrracaine hydrochloride leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride	2.03	1	0	benzoate ester
chelidamic acid [no description available]	2.03	1	0
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.03	1	0	purine nucleoside
diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.	2.03	1	0	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
cysteamine hydrochloride [no description available]	2.03	1	0
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.38	2	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
thiazoles [no description available]	1.99	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
propantheline bromide [no description available]	2.03	1	0	xanthenes
hydralazine hydrochloride hydralazine hydrochloride : The hydrochloride salt of hydralazine; a direct-acting vasodilator that is used as an antihypertensive agent.	2.03	1	0	hydrochloride	antihypertensive agent; vasodilator agent
ethamivan ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.	2.03	1	0	methoxybenzenes; phenols
pargyline hydrochloride [no description available]	2.03	1	0
5-fluorouridine [no description available]	1.96	1	0	organofluorine compound; uridines	mutagen
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	2.03	1	0	mixture	bronchodilator agent; cardiotonic drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.03	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
orphenadrine hydrochloride orphenadrine hydrochloride : A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride.	2.03	1	0	hydrochloride	antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
thymidine monophosphate Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).	2.06	1	0	thymidine 5'-monophosphate	fundamental metabolite
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.39	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide: Proposed cholinesterase inhibitor.	2.03	1	0
cyproterone acetate [no description available]	2.03	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
2-aminopurine 2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.	10.31	14	2	2-aminopurines; nucleobase analogue	antimetabolite
bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.	2.03	1	0	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	2.03	1	0	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
benzohydroxamic acid [no description available]	2.05	1	0
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	2.06	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.03	1	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
tetrahydrozoline hydrochloride tetrahydrozoline hydrochloride : The hydrochloride salt of tetryzoline. It is used as a nasal decongestant.	2.03	1	0	hydrochloride	nasal decongestant; sympathomimetic agent; vasoconstrictor agent
dequalinium chloride dequalinium chloride : An organic chloride salt that is the dichloride salt of dequalinium.	2.03	1	0	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor
n-hydroxyphthalimide N-hydroxyphthalimide: causes contact dermititis	2.05	1	0
decamethonium dibromide [no description available]	2.03	1	0
amitriptyline hydrochloride [no description available]	2.03	1	0	organic tricyclic compound
naphazoline hydrochloride [no description available]	2.03	1	0	organic molecular entity
doxylamine succinate [no description available]	2.03	1	0	organic molecular entity
carbamylhydrazine monohydrochloride [no description available]	2.03	1	0	organic molecular entity
formestane [no description available]	2.03	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lactulose [no description available]	2.06	1	0	glycosylfructose	gastrointestinal drug; laxative
debrisoquin sulfate [no description available]	2.03	1	0	organic sulfate salt
betaine hydrochloride [no description available]	2.03	1	0
bethanechol chloride bethanechol chloride : The chloride salt of bethanechol. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	2.03	1	0	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	2.05	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.03	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
benzydamine Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.	2.06	1	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
docosanol Tadenan: from powdered bark of Pygaeum africanum (Rosaceae), see also heading for docosanol (a priciple ingredient of extract). docosan-1-ol : A long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It is a non-prescription medicine approved by the FDA to shorten healing time of cold sores.. docosanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of twenty-two carbon atoms.	3.13	1	0	docosanol; long-chain primary fatty alcohol	antiviral drug; plant metabolite
hempa Hempa: A chemosterilant agent that is anticipated to be a carcinogen.	1.97	1	0	phosphoramide	insect sterilant; mutagen
Mecamylamine hydrochloride [no description available]	2.03	1	0	monoterpenoid
vinblastine [no description available]	2.42	2	0
deoxycytidine [no description available]	4.88	11	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	5.87	32	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2'-deoxyadenosine 2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source	1.98	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cyproheptadine hydrochloride (anhydrous) cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate.	2.03	1	0	hydrochloride
deoxycytidine monophosphate Deoxycytidine Monophosphate: Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions.. 2'-deoxycytosine 5'-monophosphate : A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having cytosine as the nucleobase.	2.06	1	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; mouse metabolite
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.06	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
5-chlorouracil 5-chlorouracil : An organochlorine compound consisting of uracil having an chloro substituent at the 5-position.	1.96	1	0	organochlorine compound
5 alpha-androstane-3 alpha,17 beta-diol 5alpha-androstane-3alpha,17beta-diol : The 5alpha-stereoisomer of androstane-3alpha,17beta-diol.	2.03	1	0	androstane-3alpha,17beta-diol	Daphnia magna metabolite; human metabolite
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	2.06	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	4.41	4	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
azetidyl-2-carboxylic acid azetidyl-2-carboxylic acid: a proline analog (with 4-membered ring in place of 5); a toxic non-protein amino acid that is misincorporated into protein in place of proline; induces nonfunctional heat-shock proteins; inhibits acquired thermotolerance; RN given refers to (L)-isomer; found in beets and Liliaceae. (S)-azetidine-2-carboxylic acid : The (S)-enantiomer of azetidine-2-carboxylic acid.. azetidinecarboxylic acid : A member of the class of azetidines that is azetidine substituted by at least one carboxy group at unspecified position.	2.03	1	0	azetidine-2-carboxylic acid
guanoxan guanoxan: was MH 1976-92 (see under GUANIDINES 1976-90); use GUANIDINES to search GUANOXAN 1976-92; antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage	2.06	1	0	benzodioxine
muscarine [no description available]	2.03	1	0
antazoline hydrochloride [no description available]	2.03	1	0
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.73	3	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.68	3	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
cyclic cmp Cyclic CMP: A cyclic nucleotide formed from CYTIDINE TRIPHOSPHATE by the action of cytidylate cyclase. It is a potential cyclic nucleotide intracellular mediator of signal transductions.. 3',5'-cyclic CMP : A 3',5'-cyclic pyrimidine nucleotide having cytosine as the nucleobase.	1.96	1	0	3',5'-cyclic pyrimidine nucleotide	human metabolite
meclofenoxate hydrochloride [no description available]	2.03	1	0
streptomycin [no description available]	2.44	2	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
clonidine hydrochloride [no description available]	2.03	1	0	dichlorobenzene
cladribine [no description available]	2	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
beclomethasone [no description available]	2.03	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.03	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.06	1	0	penicillin allergen; penicillin	antibacterial drug
mexiletine hydrochloride mexiletine hydrochloride : A hydrochloride composed of equimolar amounts of mexiletine and hydrogen chloride.	2.03	1	0	hydrochloride	anti-arrhythmia drug
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	9.77	36	2	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
acetylpyruvic acid acetylpyruvic acid: structure. acetylpyruvic acid : A dioxo monocarboxylic acid that is pentanoic acid carrying two oxo groups at positions 2 and 4.	2.05	1	0	beta-diketone; dioxo monocarboxylic acid	bacterial metabolite
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	2.06	1	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
cyclophosphamide cyclophosphamide hydrate : The monohydrate of cyclophosphamide.	2.03	1	0	hydrate	alkylating agent; antineoplastic agent; carcinogenic agent; immunosuppressive agent
suxamethonium chloride succinylcholine chloride (anhydrous) : A chloride salt in which the negative charge of the chloride ions is balanced by succinylcholine dications.	2.03	1	0	chloride salt	muscle relaxant
cyclobenzaprine hydrochloride cyclobenzaprine hydrochloride : The hydrochloride salt of cyclobenzaprine. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm.	2.03	1	0	hydrochloride	antidepressant; muscle relaxant
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.03	1	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
3-deazaadenosine 3-deazaadenosine: RN given refers to parent cpd.	2.69	3	0
ampicillin trihydrate [no description available]	2.05	1	0	hydrate
metoclopramide hydrochloride metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride.	2.03	1	0
isoetharine mesylate [no description available]	2.03	1	0
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	3.59	8	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
propionylpromazine hydrochloride [no description available]	2.03	1	0
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.03	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.	1.96	1	0	diatomic bromine
nsc-145,668 [no description available]	2.03	1	0	hydrochloride	antimetabolite; antineoplastic agent
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	2.03	1	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
reproterol reproterol: RN given refers to cpd without isomeric designation; structure	2.06	1	0	oxopurine
arabinofuranosylcytosine triphosphate Arabinofuranosylcytosine Triphosphate: A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.	1.96	1	0
benserazide hydrochloride benserazide hydrochloride : A hydrochloride that is the monohydrochloride salt of benserazide. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide hydrochloride has no antiparkinson actions when given alone.	2.03	1	0	hydrochloride	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	4.04	2	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.03	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.03	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.03	1	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
metergoline Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.	2.03	1	0	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
lisuride Lisuride: An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).	2.03	1	0	monocarboxylic acid amide	antidyskinesia agent; antiparkinson drug; dopamine agonist; serotonergic agonist
1-deoxynojirimycin 1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.	4.04	2	0	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	4.04	2	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
disopyramide phosphate [no description available]	2.03	1	0	organoammonium phosphate
2,6-diaminopurine 9H-purine-2,6-diamine : A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups.	2.02	1	0	2,6-diaminopurines; primary amino compound	antineoplastic agent
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.45	2	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
ergocristine ergocristine: an ergot alkaloid; one of the three components of ergotoxine; has alpha blocking action, stimulates smooth muscles & antagonizes serotonin; used as oxytocic & in peripheral disorders; minor descriptor (77-86); on-line & INDEX MEDICUS search EROLINES (77-86); RN given refers to ((5'alpha)-isomer). ergocristine : Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5', 12' and 2' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.	2.03	1	0	ergot alkaloid
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.03	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
alovudine [no description available]	2.86	3	0	pyrimidine 2',3'-dideoxyribonucleoside
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.06	1	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.06	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
almitrine Almitrine: A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.. almitrine : A triamino-1,3,5-triazine compound having allylamino substituents at the 2- and 4-positions and a 4-(bis(p-fluorophenyl)methyl)-1-piperazinyl group at the 6-position.	2.06	1	0	piperazines; triamino-1,3,5-triazine	central nervous system stimulant
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	2.06	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.	1.96	1	0
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	5.12	14	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.06	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.03	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
buspirone hydrochloride buspirone hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of buspirone and hydrogen chloride.	2.03	1	0	hydrochloride	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
etoposide [no description available]	2.49	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
propafenone hydrochloride propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias.	2.03	1	0	hydrochloride	anti-arrhythmia drug
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	2.06	1	0	penicillin allergen; penicillin	antibacterial drug
avridine [no description available]	1.96	1	0	amino alcohol
etazolate hydrochloride [no description available]	2.03	1	0
butaclamol [no description available]	2.03	1	0	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
ribavirin Rebetron: Rebetron is tradename	9.1	53	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
carbidopa [no description available]	2.03	1	0	catechols; hydrate; hydrazines; monocarboxylic acid	antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	2.03	1	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.45	2	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.06	1	0
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.03	1	0	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
dexibuprofen dexibuprofen: structure in first source	2.03	1	0	ibuprofen	non-narcotic analgesic; non-steroidal anti-inflammatory drug
quisqualic acid Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.	2.03	1	0	non-proteinogenic alpha-amino acid
pirfenidone pirfenidone : A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.	2.03	1	0	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flecainide acetate flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.03	1	0	acetate salt	anti-arrhythmia drug
nicardipine hydrochloride [no description available]	2.03	1	0	dihydropyridine	geroprotector
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	4.04	2	0	benzamides; carboxylic ester
arildone [no description available]	4.44	1	1	methoxybenzenes
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.03	1	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
laurocapram laurocapram: enhances percutaneous absorption of different chemicals; structure given in first source	1.99	1	0
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	4.41	4	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
staurosporine [no description available]	3.78	2	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
terazosin hydrochloride anhydrous [no description available]	2.03	1	0
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	1.96	1	0	one-carbon compound; organic sodium salt	antiviral drug
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.03	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
ranitidine hydrochloride label : A role played by a part of a molecular entity distinguishable by the observer but not by the system and used to identify a tracer.	2.03	1	0
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	2.03	1	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
nedocromil Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.	2.06	1	0	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
fiacitabine fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.	5.87	10	0
fialuridine [no description available]	3.23	6	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.03	1	0	cephalosporin	antibacterial drug; drug allergen
alo 2145 apraclonidine hydrochloride : The hydrochloride salt of apraclonidine.	2.03	1	0	hydrochloride	alpha-adrenergic agonist; antiglaucoma drug
recainam recainam: structure given in first source	2.06	1	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	4.23	3	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
tolrestat tolrestat: RN & structure given in first source	2.06	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
rimcazole rimcazole: RN given refers to (cis)-isomer; structure given in first source	4.04	2	0	carbazoles
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.03	1	0	aromatic ketone
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.06	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	2.03	1	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
raloxifene hydrochloride Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.	2.03	1	0	hydrochloride	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.03	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
quinpirole hydrochloride [no description available]	2.03	1	0
imazodan imazodan: RN & structure given in first source;	2.03	1	0
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	3.13	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.63	9	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	7.54	68	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
mibefradil dihydrochloride [no description available]	2.03	1	0
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.06	1	0	tetralins	T-type calcium channel blocker
tenidap tenidap: structure given in first source; RN refers to (Z)-isomer	2.06	1	0
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.15	5	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
lamivudine [no description available]	3.02	4	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
aptiganel hydrochloride [no description available]	2.03	1	0
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.06	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	2.06	1	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.78	3	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.05	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	8.86	3	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.39	2	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
phenelzine sulfate [no description available]	2.03	1	0	organic molecular entity
fluoxetine hydrochloride fluoxetine hydrochloride : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine hydrochloride. A selective serotonin reuptake inhibitor (SSRI), it is used for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.	2.03	1	0	hydrochloride; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
propranolol hydrochloride Inderex: combination of above cpds; used in treatment of hypertension	2.03	1	0	hydrochloride
bupropion hydrochloride [no description available]	2.03	1	0	aromatic ketone
diltiazem hydrochloride Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.	2.03	1	0	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.03	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.03	1	0
doxazosin mesylate Cardura: Trade name in United States.	2.03	1	0	methanesulfonate salt	geroprotector
terfenadine [no description available]	2.03	1	0	diarylmethane
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.45	2	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.05	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
amantadine hydrochloride [no description available]	2.03	1	0	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.03	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
chloroquine diphosphate [no description available]	2.03	1	0
1,5-anhydroglucitol 1,5-anhydroglucitol: structure. 1,5-anhydro-D-glucitol : An anhydro sugar of D-glucitol.	1.96	1	0	anhydro sugar	human metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	1.99	1	0	organic bromide salt	colorimetric reagent; dye
thymidine 5'-triphosphate thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.	2.39	2	0	pyrimidine 2'-deoxyribonucleoside 5'-triphosphate; thymidine phosphate	Escherichia coli metabolite; mouse metabolite
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine [no description available]	2.44	2	0
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.43	2	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	2.05	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	3.94	12	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
thymine arabinoside thymine arabinoside: selectively inhibits replication of herpes simplex virus	5.33	18	0	N-glycosyl compound
ibacitabine ibacitabine: antiherpetic agent	2.39	2	0	pyrimidine 2'-deoxyribonucleoside
2'-deoxyuridylic acid 2'-deoxyuridylic acid: RN given refers to parent cpd	2.43	2	0	deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; metabolite; mouse metabolite
phosphoramidic acid phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds	2.95	4	0	phosphoric acid derivative
6-aminothymine 6-aminothymine: inhibits degradation of nucleosides (idoxuridine, thymidine) & pyrimidine bases	2.66	3	0
5'-amino-2',5'-dideoxythymidine 5'-amino-5'-deoxythymidine: RN given refers to parent cpd	3.06	1	0
dobutamine hydrochloride dobutamine hydrochloride : The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure.	2.03	1	0	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
desipramine hydrochloride desipramine hydrochloride : The hydrochloride salt of desipramine.	2.03	1	0	hydrochloride	drug allergen
dopamine hydrochloride P 498: structure in first source; do not confuse with dopamine chloride, also known as P 498	2.03	1	0	catecholamine
proadifen hydrochloride [no description available]	2.03	1	0
3'-azido-3'-deoxythymidine 5'phosphate 3'-azido-3'-deoxythymidine 5'phosphate: inhibits thymidylate kinase	2.06	1	0
4-nitrobenzylthioinosine 4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1	2.03	1	0	purine nucleoside
5-chloro-2'-deoxyuridine [no description available]	1.96	1	0
5-(2-propenyl)-2'-deoxyuridine [no description available]	1.96	1	0
metrifudil [no description available]	2.03	1	0
rutecarpine rutacarpine: from Evodia rutaecarpa; an ingredient in zhuyu hewei zhitong capsules	2.03	1	0	beta-carbolines
trihexyphenidyl hydrochloride [no description available]	2.03	1	0	aralkylamine
thioridazine hydrochloride [no description available]	2.03	1	0	hydrochloride	first generation antipsychotic; geroprotector
procainamide hydrochloride procainamide hydrochloride : A hydrochloride which has procainamide as the amino component.	2.03	1	0	hydrochloride	anti-arrhythmia drug
siquil [no description available]	2.03	1	0	hydrochloride	anticoronaviral agent
sotalol hydrochloride sotalol hydrochloride : A hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.03	1	0	hydrochloride	anti-arrhythmia drug; beta-adrenergic antagonist
oxymetazoline hydrochloride oxymetazoline hydrochloride : A hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal congestion.	2.03	1	0	hydrochloride	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
alprenolol hydrochloride [no description available]	2.03	1	0	hydrochloride
edoxudin [no description available]	4.78	10	0	pyrimidine 2'-deoxyribonucleoside
2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.	2.03	1	0	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
fluphenazine hydrochloride [no description available]	2.03	1	0	phenothiazines	anticoronaviral agent
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.15	1	0	1,2,3-triazole
tryptamine monohydrochloride [no description available]	2.03	1	0
clomipramine hydrochloride clomipramine hydrochloride : A hydrochloride resulting from the reaction of equimolar amounts of clomipramine and hydrogen chloride. One of the more sedating tricyclic antidepressants, it is used for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.03	1	0	hydrochloride	anticoronaviral agent; antidepressant; serotonergic antagonist; serotonergic drug
amiloride hydrochloride amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.	2.03	1	0	hydrate	diuretic; sodium channel blocker
prazosin hydrochloride [no description available]	2.03	1	0	hydrochloride
mianserin hydrochloride mianserin hydrochloride : The hydrochloride salt of mianserin, a tetracyclic compound with antidepressant effects.	2.03	1	0	hydrochloride	geroprotector
lomefloxacin hydrochloride lomefloxacin hydrochloride : The hydrochloride salt of lomefloxacin. It is administered by mouth to treat bacterial infections including bronchitis and urinary tract infections. It is also used topically as eye drops for the treatment of bacterial conjunctivitis, and as ear drops for the treatment of otitis externa and otitis media.	2.03	1	0	hydrochloride	antimicrobial agent; antitubercular agent; photosensitizing agent
fenspiride hydrochloride [no description available]	2.03	1	0
nilverm [no description available]	2.03	1	0	organic molecular entity
sanguinarine chloride [no description available]	2.03	1	0
arbekacin arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.	2.06	1	0	aminoglycoside; kanamycins	antibacterial agent; antibacterial drug; antimicrobial agent; protein synthesis inhibitor
ropinirole hydrochloride [no description available]	2.03	1	0	indoles
plasmenylserine plasmenylserine: RN given refers to (L)-isomer. O-phospho-L-serine : The L-enantiomer of O-phosphoserine.. O-phosphoserine : A serine derivative that is serine substituted at the oxygen atom by a phosphono group.	2.03	1	0	O-phosphoserine	EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
5-aminovaleric acid hydrochloride [no description available]	2.03	1	0
2-phenylimidazole [no description available]	2.05	1	0
5-iodouracil 5-iodouracil: RN given refers to parent cpd. 5-iodouracil : An organoiodine compound consisting of uracil having an iodo substituent at the 5-position.	1.96	1	0	organoiodine compound	antimetabolite
2-Oxo-4-phenylbutyric acid [no description available]	2.05	1	0	benzenes
n-acetyltryptamine N-acetyltryptamine: antagonizes the melatonin-induced inhibition of dopamine release from retina; RN given refers to parent cpd. N-acetyltryptamine : A tryptamine compound having an acetyl substituent attached to the side-chain amino function.	2.03	1	0	acetamides; indoles
D-serine [no description available]	2.03	1	0	D-alpha-amino acid; serine zwitterion; serine	Escherichia coli metabolite; human metabolite; NMDA receptor agonist
pafenolol pafenolol: structure given in first source	2.06	1	0
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	2.06	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
dihydroergotamine mesylate dihydroergotamine mesylate : The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotension.	2.03	1	0	methanesulfonate salt	non-narcotic analgesic; serotonergic agonist; vasoconstrictor agent
ranolazine hydrochloride [no description available]	2.03	1	0
loxapine succinate [no description available]	2.03	1	0	succinate salt	geroprotector
guanfacine hydrochloride [no description available]	2.03	1	0	acetamides	geroprotector
pirenzepine dihydrochloride [no description available]	2.03	1	0	hydrochloride
labetalol hydrochloride [no description available]	2.03	1	0	salicylamides
acecainide hydrochloride [no description available]	2.03	1	0
loperamide hydrochloride loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	2.03	1	0	hydrochloride	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
maprotiline hydrochloride [no description available]	2.03	1	0	anthracenes
protoporphyrin ix, disodium salt [no description available]	2.03	1	0
siguazodan [no description available]	2.03	1	0	pyridazinone
3-octadecanamido-2-ethoxypropylphosphocholine 3-octadecanamido-2-ethoxypropylphosphocholine: anti-HIV agent; RN & structure given in first source	2.03	1	0
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine [no description available]	2.71	3	0
9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine 9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine: RN refers to (S)-isomer	2.05	1	0
chelerythrine chloride [no description available]	2.03	1	0
clevudine [no description available]	2.67	3	0
n-(2-(hydroxyethoxy)methyl)-5-methyluracil N-(2-(hydroxyethoxy)methyl)-5-methyluracil: structure given in first source	2.39	2	0
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil 5-fluoro-1-((2-hydroxyethoxy)methyl)uracil: structure given in first source	2.39	2	0
4'-thiothymidine [no description available]	1.97	1	0
3-deazaaristeromycin 3-deazaaristeromycin: antagonist of S-adenosylhomocysteinase	2.38	2	0
neplanocin a neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase	1.98	1	0
tosyllysine chloromethyl ketone [no description available]	2.03	1	0
9-(2,3-dihydroxypropyl)adenine, (s)-isomer [no description available]	4.49	22	0
5-ethyluracil 5-ethyluracil: antagonist of dihydrouracil dehydrogenase (NADP)	1.96	1	0
5-(n-methyl-n-isobutyl)amiloride 5-(N-methyl-N-isobutyl)amiloride: inhibitor of the Na+-H+ antiporter	2.03	1	0
1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride : A hydrochloride salt prepared from anileridine and two molar equivalents of hydrogen chloride.	2.03	1	0	hydrochloride	EC 2.7.11.13 (protein kinase C) inhibitor
amperozide hydrochloride amperozide hydrochloride : The hydrochloride salt of amperozide.	2.03	1	0	hydrochloride	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
pyrrolidine dithiocarbamic acid [no description available]	2.03	1	0
agroclavine agroclavine: structure. agroclavine : An ergot alkaloid that is ergoline which contains a double bond between positions 8 and 9, and which is substituted by methyl groups at positions 6 and 8.	2.03	1	0	ergot alkaloid
s-methylisothiourea sulfate [no description available]	2.03	1	0
p-Aminobenzamidine dihydrochloride [no description available]	2.03	1	0	organic molecular entity
rivastigmine [no description available]	2.06	1	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
benzamidine hydrochloride [no description available]	2.03	1	0
6-amino-5-bromouracil [no description available]	1.96	1	0
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.03	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
methionine sulfoximine L-methionine sulfoximine : A methionine sulfoximine in which the amino group has S-stereochemistry.	2.03	1	0	L-alpha-amino acid zwitterion; L-methionine derivative; methionine sulfoximine; non-proteinogenic L-alpha-amino acid	EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor; geroprotector
tretazicar tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)	2.03	1	0
carbetapentane citrate [no description available]	2.03	1	0	carbonyl compound
moexipril [no description available]	2.06	1	0	peptide
phentolamine mesylate [no description available]	2.03	1	0
mephentermine sphinganine : A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration.	2.03	1	0	2-aminooctadecane-1,3-diol	EC 2.7.11.13 (protein kinase C) inhibitor; human metabolite; mouse metabolite
oxybutynin hydrochloride [no description available]	2.03	1	0	hydrochloride
5-hydroxymethyl-2'-deoxyuridine [no description available]	2.03	1	0	pyrimidine 2'-deoxyribonucleoside
nimustine nimustine hydrochloride : A hydrochloride obtained by combining nimustine with one equivalent of hydrochloric acid. An antineoplastic agent especially effective against malignant brain tumors.	2.03	1	0	hydrochloride	antineoplastic agent
cordium bepridil hydrochloride monohydrate : The hydrochloride monohydrate of bepridril.	2.03	1	0	hydrate; hydrochloride
L-2-aminoadipic acid L-2-aminoadipic acid : The L-enantiomer of 2-aminoadipic acid.	2.03	1	0	2-aminoadipic acid	Escherichia coli metabolite; human metabolite
prilocaine hydrochloride prilocaine hydrochloride : The monohydrochloride salt of prilocaine.	2.03	1	0	hydrochloride	local anaesthetic
lekoptin (S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.	4.04	2	0	2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
mor-14 N-methyldeoxynojirimycin: glucosidase inhibitor	2.03	1	0	hydroxypiperidine; piperidine alkaloid; tertiary amino compound	anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite
lopinavir [no description available]	2.05	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
brexanolone brexanolone: a mixture of allopregnanolone and sulfobutylether‐beta‐cyclodextrin for treatment of postpartum depression. brexanolone : A 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women.	2.03	1	0	3-hydroxy-5alpha-pregnan-20-one	antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative
msh release-inhibiting hormone [no description available]	2.03	1	0	oligopeptide
bromodeoxyuridylate bromodeoxyuridylate: RN given refers to parent cpd	2.4	2	0
phenylisopropyladenosine [no description available]	2.03	1	0	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
hexamethonium chloride [no description available]	2.03	1	0
6-(4-nitrobenzylthio)guanosine 6-(4-nitrobenzylthio)guanosine: inhibitor of nucleoside transport	2.03	1	0
5-hydroxy-2'-deoxyuridine 5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine	2.03	1	0
6-methylpurine riboside [no description available]	1.98	1	0
3-aminopropylphosphonic acid 3-aminopropylphosphonic acid: RN given refers to parent cpd; structure. (3-aminopropyl)phosphonic acid : A phosphonic acid in which the hydrogen attached to the phosphorus of phosphonic acid is substituted by a 3-aminopropyl group. It is a partial agonist of GABAB receptors.	2.03	1	0	phosphonic acids; primary amino compound; zwitterion	GABAB receptor agonist
5-formyl-2'-deoxyuridine 5-formyl-2'-deoxyuridine: structure given in first source	2.03	1	0
5'-n-methylcarboxamideadenosine 5'-N-methylcarboxamideadenosine: RN given refers to (beta-D)-isomer	2.03	1	0
3,7-dimethyl-1-propargylxanthine 3,7-dimethyl-1-propargylxanthine: potent & selective in vivo antagonist of adenosine analogs	2.03	1	0
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.03	1	0
n(6)-phenyladenosine [no description available]	2.03	1	0	purine nucleoside
tetrahydrodeoxycorticosterone tetrahydrodeoxycorticosterone: RN given refers to (3alpha,5beta)-isomer	2.03	1	0	21-hydroxy steroid
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.03	1	0	methyladenosine
mizoribine [no description available]	2.03	1	0	imidazoles	anticoronaviral agent
1-amino-1,3-dicarboxycyclopentane 1-amino-1,3-dicarboxycyclopentane: RN given refers to (cis)-isomer	2.03	1	0
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	2.03	1	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.06	1	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
alphaxalone alphaxalone: RN given refers to (3alpha,5alpha)-isomer; structure	2.03	1	0	corticosteroid hormone
s-nitrosoglutathione [no description available]	2.03	1	0	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
cp-55,940 [no description available]	2.03	1	0
vanoxerine vanoxerine dihydrochloride : A hydrochloride salt that is obtained by reaction of vanoxerine with two equivalents of hydrogen chloride. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.	2.03	1	0	hydrochloride	dopamine uptake inhibitor
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate: structure given in first source	2.03	1	0	beta-carbolines
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	2.03	1	0	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
cv 3988 CV 3988: platelet activating factor antagonist; structure given in first source	2.03	1	0
beta-carboline-3-carboxylic acid methyl ester beta-carboline-3-carboxylic acid methyl ester: structure given in first source	2.03	1	0	beta-carbolines
methoctramine methoctramine: structure given in first source. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.	2.03	1	0	hydrochloride	muscarinic antagonist
hypotaurine [no description available]	2.03	1	0	aminosulfinic acid; zwitterion	human metabolite; metabolite; mouse metabolite
dihydrokainate [no description available]	2.03	1	0	dicarboxylic acid
gabazine [no description available]	2.03	1	0
cl 218872 CL 218872: shows specific action on benzodiazepine receptors; structure	2.03	1	0	pyridazines; ring assembly
betaxolol hydrochloride betaxolol hydrochloride : The hydrochloride salt of betaxolol.	2.03	1	0	hydrochloride	antihypertensive agent; beta-adrenergic antagonist
catechin (+)-catechin monohydrate : The monohydrate of (+)-catechin.	2.03	1	0	hydrate	geroprotector
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine NAN 190 hydrobromide : A hydrobromide obtained by reaction of NAN 190 with one equivalent of hydrobromic acid.	2.03	1	0	hydrobromide	serotonergic antagonist
s-methylthiocitrulline S-methylthiocitrulline: a nitric oxide synthase inhibitor; structure in first source. S-methyl-L-thiocitrulline : An L-arginine derivative in which the guanidino NH2 group of L-arginine is replaced by a methylsufanyl group.	2.03	1	0	imidothiocarbamic ester; L-arginine derivative; L-ornithine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; neuroprotective agent
dihydrocapsaicin [no description available]	2.03	1	0	capsaicinoid
ml 9 [no description available]	2.03	1	0
parthenolide [no description available]	2.03	1	0	germacranolide
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	1.96	1	0
9-(2,3-dihydroxypropyl)adenine [no description available]	3.46	2	0
3',4'-dichlorobenzamil 3',4'-dichlorobenzamil: inhibits Na-Ca exchange in membrane vesicle & papillary muscle preparations from guinea pig heart	2.03	1	0	guanidines; pyrazines
1-(carboxymethylthio)tetradecane 1-(carboxymethylthio)tetradecane: structure given in first source; alkylthio acetic acid, non-beta-oxidizable	2.03	1	0	straight-chain fatty acid
2-iodomelatonin [no description available]	2.03	1	0	acetamides
arcaine, sulfate [no description available]	2.03	1	0
5-methoxymethyl-2'-deoxyuridine 5-methoxymethyl-2'-deoxyuridine: used in treatment of experimental herpes simplex keratitis	2.65	3	0
gr 113808 GR 113808: structure given in first source; a 5-HT(4) receptor antagonist: GR 125487 is the HCl salt. GR 113808 : An indolyl carboxylate ester obtained by formal condensation between the carboxy group of 1-methylindole-3-carboxylic acid with the hydroxy group of N-{2-[4-(hydroxymethyl)piperidin-1-yl]ethyl}methanesulfonamide.	2.03	1	0	indolyl carboxylate ester; piperidines; sulfonamide	serotonergic antagonist
gallopamil hydrochloride [no description available]	2.03	1	0
gamma-glutamylaminomethylsulfonic acid [no description available]	2.03	1	0
buthionine sulfoximine L-buthionine-(S,R)-sulfoximine : A 2-amino-4-(S-butylsulfonimidoyl)butanoic acid which has S-configuration. It is a inhibitor of gamma-glutamylcysteine synthetase and glutathione (GSH) biosynthesis and is capable of enhancing the apoptotic effects of several chemotherapeutic agents.	2.03	1	0	2-amino-4-(S-butylsulfonimidoyl)butanoic acid	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
sb 204070a SB 204070A: structure given in first source; a selective 5-HT(4) receptor antagonist	2.03	1	0
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine LY 165163: structure given in first source; a serotonin agonist. LY-165163 : A N-arylpiperazine that is piperazine substituted by 2-(4-aminophenyl)ethyl and 3-(trifluoromethyl)phenyl groups at positions 1 and 4, respectively. It is a selective 5-HT1A serotonin receptor agonist and 5-HT1D serotonin receptor antagonist.	2.03	1	0	(trifluoromethyl)benzenes; N-alkylpiperazine; N-arylpiperazine; primary arylamine; substituted aniline	geroprotector; serotonergic agonist
l 655240 L 655240: thromboxane and prostaglandin endoperoxide receptor antagonist; structure given in first source; RN given is for parent cpd	2.03	1	0	methylindole
san 58035 [no description available]	2.03	1	0
4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine: structure given in first source; 5-bromotubercidin in which the ribose is replaced by 2-hydroxyethoxymethyl	2.05	1	0
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine: prodrug for HPMPC; specific name and structure not given in first source	2.44	2	0
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	2.06	1	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
nnc 711 NNC 711: structure in first source	2.03	1	0
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide: a highly-selective, nonpeptide delta opioid receptor agonist; structure given in first source	2.03	1	0	diarylmethane
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.03	1	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
5'-amino-5-iodo-2',5'-dideoxyuridine [no description available]	4.26	3	0
azetidine-2,4-dicarboxylic acid azetidine-2,4-dicarboxylic acid: activates neuronal metabotropic receptors; RN given refers to (trans-isomer); RN for cpd without isomeric designation not avail 10/93	2.03	1	0
bd 1008 BD 1008: structure in first source	4.04	2	0	primary amine
pre 084 2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate: structure given in first source	2.03	1	0	morpholines
5-vinyl-1-arabinofuranosyluracil 5-vinyl-1-arabinofuranosyluracil: RN given refers to beta-(D)-isomer	2.88	4	0
5'-noraristeromycin 5'-noraristeromycin: structure given in first source	1.98	1	0
methotrexate [no description available]	2.7	3	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol 1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol: irreversibly inactivates the dihydroalprenolol binding site; alprenolol analog; isopropylamino group of alprenolol replaced by 8-bromoacetylamino-1-amino-p-menthane moiety in the 1 position; structure given in first source	2.03	1	0
sr 2640 SR 2640: leukotriene D4 and E4 antagonist	2.03	1	0	quinolines
ici 204448 [no description available]	2.03	1	0
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride 4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride: has high affinity and selectivity for 5-HT3 receptors; structure given in first source	2.03	1	0
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis	2.03	1	0	phenylindole
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist	2.03	1	0
8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine: structure given in first source	2.03	1	0
5-bromoethynyl-2'-deoxyuridine 5-bromoethynyl-2'-deoxyuridine: structure given in first source	1.96	1	0
l 741626 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole: structure in first source	2.03	1	0	piperidines
nisoxetine hydrochloride [no description available]	2.03	1	0
ng-nitroarginine methyl ester N(gamma)-nitro-L-arginine methyl ester hydrochloride : A hydrochloride obtained by combining N(gamma)-nitro-L-arginine methyl ester with one equivalent of hydrochloric acid.	2.03	1	0	hydrochloride	EC 1.14.13.39 (nitric oxide synthase) inhibitor
tilarginine acetate [no description available]	2.03	1	0
alpha-guanidinoglutaric acid alpha-guanidinoglutaric acid: identified in the convulsive period of cobalt-induced seizures from cat cerebral cortex; RN given for cpd with unspecified guanidino-locant	2.03	1	0	L-glutamic acid derivative
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer [no description available]	2.03	1	0
5-nitro-2'-deoxyuridine [no description available]	2.03	1	0
imidazole-4-acetic acid hydrochloride [no description available]	2.03	1	0
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.21	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
nsc-141549 [no description available]	2.03	1	0
5-vinyl-2'-deoxyuridine 5-vinyl-2'-deoxyuridine: structure	2.89	4	0
2-chloro-2-deoxyglucose [no description available]	2.03	1	0
vx 497 N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source	4.04	2	0
bcx 1812 [no description available]	2.05	1	0	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
idazoxan hydrochloride [no description available]	2.03	1	0
isoguvacine hydrochloride [no description available]	2.03	1	0
8-methoxymethyl-3-isobutyl-1-methylxanthine 8-methoxymethyl-3-isobutyl-1-methylxanthine: inhibitor of phosphodiesterase I	2.03	1	0	oxopurine
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.06	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
1-deazaadenosine 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source	1.99	1	0
5-propyl-2'-deoxyuridine 5-propyl-2'-deoxyuridine: RN given refers to parent cpd	3.08	5	0
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.03	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
Serotonin hydrochloride [no description available]	2.03	1	0	tryptamines
n-phthaloylglutamic acid N-phthaloyl-L-glutamic acid : A glutamic acid derivative that is L-glutamic acid in which the two hydrogens on the amino group are substituted by a phthaloyl group.	2.03	1	0	L-glutamic acid derivative; phthalimides
1,3-dipropyl-7-methylxanthine 1,3-dipropyl-7-methylxanthine: structure given in first source	2.03	1	0
ag 3-5 icilin: a cooling compound that activates TRPM8	2.03	1	0	C-nitro compound
5-trifluoromethyl-2'-deoxyuridylic acid [no description available]	1.96	1	0
n-n-propylnorapomorphine [no description available]	2.03	1	0	aporphine alkaloid
urapidil monohydrochloride [no description available]	2.03	1	0
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	2.39	2	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
azepexole, dihydrochloride [no description available]	2.03	1	0
2,5-dimethoxy-4-iodoamphetamine hydrochloride [no description available]	2.03	1	0
abt 980 [no description available]	2.03	1	0
sk&f 75670 SK&F 75670: RN refers to HBr; N-methyl derivative of SK&F 38393	2.03	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.06	1	0
esatenolol esatenolol : The (S)-enantiomer of atenolol.	2.03	1	0	atenolol	beta-adrenergic antagonist
nbi 27914 [no description available]	2.03	1	0	dialkylarylamine; tertiary amino compound
sb 216763 [no description available]	2.03	1	0	indoles; maleimides
erlotinib [no description available]	3.51	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	5.82	12	0	divalent inorganic anion; phosphite ion
(R)-atenolol (R)-atenolol : The (R)-enantiomer of atenolol.	2.03	1	0	atenolol
memantine hydrochloride [no description available]	2.03	1	0	hydrochloride	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
pefabloc [no description available]	2.03	1	0
2'-deoxyaristeromycin [no description available]	1.97	1	0
pongidae [no description available]	2.03	1	0
succinylproline [no description available]	2.03	1	0	N-acyl-amino acid
n(4)-hydroxycytidine N(4)-hydroxycytidine : A nucleoside analogue that is cytidine which carries a hydroxy group at the N(4)-positon. It has broad-spectrum antiviral activity against influenza, SARS-CoV , SARS-CoV-2 and MERS-CoV.	2.31	1	0	ketoxime; nucleoside analogue	anticoronaviral agent; antiviral agent; drug metabolite; human xenobiotic metabolite
sb 205384 SB 205384: structure in first source	2.03	1	0	thienopyridine
hydrastine [no description available]	2.03	1	0	isoquinolines	metabolite
gabaculine hydrochloride [no description available]	2.03	1	0
etiron monohydrobromide [no description available]	2.03	1	0
bmy 7378 [no description available]	2.03	1	0
vesamicol [no description available]	2.03	1	0
cortisone [no description available]	2.03	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
vincristine sulfate [no description available]	2.03	1	0	organic sulfate salt	antineoplastic agent; geroprotector
n-methylserotonin oxalate salt [no description available]	2.03	1	0
nsc 95397 [no description available]	2.03	1	0	1,4-naphthoquinones
emimycin [no description available]	2.17	1	0
wortmannin [no description available]	2.03	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
1-(benzenesulfonyl)indole [no description available]	2.05	1	0	sulfonamide
2'-fluorothymidine [no description available]	3.06	5	0
rimiterol rimiterol: was heading 1977-94 (see under CATECHOLS 1977-90); use CATECHOLS to search RIMITEROL 1977-94; predominantly a beta 2 stimulant, therefore affects the cardiovascular system less than isoproterenol, but its action is of shorter duration than that of albuterol	2.06	1	0	catechols
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.03	1	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
5'-deoxyadenosine 5'-deoxyadenosine: main heading DEOXYADENOSINE refers to the 3' cpd. 5'-deoxyadenosine : A 5'-deoxyribonucleoside compound having adenosine as the nucleobase.	1.99	1	0	5'-deoxyribonucleoside; adenosines	Escherichia coli metabolite; human metabolite; mouse metabolite
canavanine L-canavanine : A non-proteinogenic L-alpha-amino acid that is L-homoserine substituted at oxygen with a guanidino (carbamimidamido) group. Although structurally related to L-arginine, it is non-proteinogenic.	2.03	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	phytogenic insecticide; plant metabolite
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	1.96	1	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
raffinose Raffinose: A trisaccharide occurring in Australian manna (from Eucalyptus spp, Myrtaceae) and in cottonseed meal.. raffinose : A trisaccharide composed of alpha-D-galactopyranose, alpha-D-glucopyranose and beta-D-fructofuranose joined in sequence by 1->6 and 1<->2 glycosidic linkages, respectively.	2.06	1	0	raffinose family oligosaccharide; trisaccharide	mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
5-hydroxytryptophan hydroxytryptophan : A hydroxy-amino acid that is tryptophan substituted by at least one hydroxy group at unspecified position.. 5-hydroxy-L-tryptophan : The L-enantiomer of 5-hydroxytryptophan.	2.03	1	0	5-hydroxytryptophan; amino acid zwitterion; hydroxy-L-tryptophan; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; plant metabolite
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.45	2	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.	2.03	1	0	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
monoiodotyrosine Monoiodotyrosine: A product from the iodination of tyrosine. In the biosynthesis of thyroid hormones (THYROXINE and TRIIODOTHYRONINE), tyrosine is first iodized to monoiodotyrosine.. iodotyrosine : A tyrosine derivative which has at least one iodo-substituent on the benzyl moiety.. monoiodotyrosine : An iodotyrosine carrying a single iodo substituent.. 3-iodo-L-tyrosine : The monoiodotyrosine that is L-tyrosine carrying an iodo-substituent at position C-3 of the benzyl group.	2.03	1	0	amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2.03	1	0	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
willardiine willardiine: isolated from seeds of Acacia willariana; structure. 3-(uracil-1-yl)-L-alanine : The 3-(uracil-1-yl) derivative of L-alanine.	2.03	1	0	amino acid zwitterion; L-alanine derivative; non-proteinogenic L-alpha-amino acid
cortodoxone Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen.	2.03	1	0	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.06	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	2.06	1	0
amiodarone hydrochloride [no description available]	2.03	1	0	aromatic ketone
dicyclomine hydrochloride dicyclomine hydrochloride : The hydrochloride salt of dicyclomine. An anticholinergic, it is used to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	2.03	1	0	hydrochloride	antispasmodic drug; muscarinic antagonist
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	2.03	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
nortriptyline hydrochloride [no description available]	2.03	1	0	organic tricyclic compound	geroprotector
paromomycin sulfate paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.03	1	0
Dubinidine [no description available]	2.03	1	0	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
cyclopamine [no description available]	2.03	1	0	piperidines	glioma-associated oncogene inhibitor
s-(4-azidophenacyl)glutathione S-(4-azidophenacyl)glutathione: photoaffinity label deriv of glutathione; inhibits glyoxalase I (EC 4.4.1.5)	2.03	1	0	peptide
adenosine-5'-carboxaldehyde adenosine-5'-carboxaldehyde: potent inhibitor of S-adenosyl-L-homocysteine hydrolase; structure given in first source. 5'-dehydroadenosine : A member of the class of adenosines that is 5'-dehydro derivative of adenosine.	2.41	2	0	adenosines
hydroxylamine hydrochloride [no description available]	2.03	1	0	organic molecular entity
sb 228357 SB 228357: a neuroleptic with equivalent or higher antagonist affinity for 5-HT2 than for dopamine D2 receptor	2.03	1	0	indolyl carboxylic acid
3,5-dihydroxyphenylglycine (S)-3,5-dihydroxyphenylglycine : A glycine derivative that is L-alpha-phenylglycine substituted at positions 3 and 5 on the phenyl ring by hydroxy groups.	2.03	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid; resorcinols
actinonin actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure	2.03	1	0
vinpocetine vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation	2.03	1	0	alkaloid	geroprotector
dihydroergocristine monomesylate dihydroergocristine mesylate : The methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia.	2.03	1	0	methanesulfonate salt	alpha-adrenergic antagonist; geroprotector; vasodilator agent
acarbose [no description available]	2.06	1	0	amino cyclitol; glycoside
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.03	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.03	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
(north)-methanocarbathymidine (north)-methanocarbathymidine: also called NMCT. 1-[(1S,2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl]thymine : A carbobicyclic compound that is bicyclo[3.1.0]hexane which is substituted at the 2-pro-S, 4-pro-S and 5-pro-R positions by thymin-1-yl, hydroxy, and hydroxymethyl groups, respectively.	2.43	2	0	C-glycosyl pyrimidine; carbobicyclic compound; primary alcohol; pyrimidone; secondary alcohol
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.03	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.03	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	4.45	4	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol 5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol: estrogen receptor ligand; structure in first source. (R,R)-5,11-diethyl-5,6,11,12-tetrahydro-2,8-chrysenediol : A carbotetracyclic compound that is 5,6,11,12-tetrahydrochrysene substituted by hydroxy groups at positions 2 and 8 and by ethyl groups at positions 5 and 11 (the 5R,11R-stereoisomer). It is an agonist of ER-alpha and antagonist of ER-beta receptors.	2.03	1	0	carbotetracyclic compound; polyphenol	estrogen receptor agonist; estrogen receptor antagonist; geroprotector; neuroprotective agent
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	2.06	1	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	4.23	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid 2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid: structure in first source	2.03	1	0
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	2.03	1	0	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
L-cycloserine L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.	2.03	1	0	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	4.04	2	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.52	2	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
5-iodo-2'-deoxyuridine 5'-monophosphate iododeoxyuridylate: RN given refers to parent cpd	1.96	1	0
1,4-dideoxy-1,4-imino-d-arabinitol [no description available]	2.03	1	0
lamivudine triphosphate [no description available]	2.05	1	0
l 737126 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase	2.05	1	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	3.51	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.03	1	0	purvalanol
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.03	1	0	actinomycin	mutagen
carbocyclic 5-iodo-2'-deoxyuridine [no description available]	2.39	2	0
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.71	3	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
ic9564 IC9564: betulinic acid derivative; structure in first source	2.05	1	0
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.98	4	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
2,5,6-trichloro-1-(ribofuranosyl)benzimidazole [no description available]	2.05	1	0
gw 257406x maribavir: has antiviral activity against human cytomegalovirus	2.05	1	0
5-ethynyl-2'-deoxyuridine 5-ethynyl-2'-deoxyuridine: structure in first source	3.08	5	0
bromodeoxycytidine Bromodeoxycytidine: 5-Bromo-2'-deoxycytidine. Can be incorporated into DNA in the presence of DNA polymerase, replacing dCTP.	3.08	5	0
cmx 001 [no description available]	2.46	2	0
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.05	1	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine [no description available]	2.49	2	0
5-cyano-2'-deoxyuridine 5-cyano-2'-deoxyuridine: structure in first source	2.03	1	0
4-phenyl-4-oxo-2-hydroxybuten-2-oic acid 2,4-dioxo-4-phenylbutanoic acid: structure in first source	2.05	1	0
cf 1743 [no description available]	3.14	5	0
hevizos [no description available]	1.96	1	0	pyrimidine 2'-deoxyribonucleoside
2-hydroxy-4h-isoquinoline-1,3-dione 2-hydroxy-4H-isoquinoline-1,3-dione: structure in first source	2.05	1	0
5-(2-chloroethyl)-2'-deoxyuridine 5-(2-chloroethyl)-2'-deoxyuridine: inhibitor of herpes viruses; structure given in first source	3.47	8	0	pyrimidine 2'-deoxyribonucleoside
isoliquiritigenin [no description available]	2.03	1	0	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
rauwolscine Rauwolscine: A stereoisomer of yohimbine.	2.03	1	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	3.06	1	0	diphosphate ion
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.03	1	0	benzamides
calmidazolium calmidazolium chloride : The organic choride salt of calmidazolium.	2.03	1	0	organic chloride salt	apoptosis inducer; calmodulin antagonist
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	2.06	1	0	penicillin allergen; penicillin	antibacterial drug
amygdalin (R)-amygdalin : An amygdalin in which the stereocentre on the cyanohydrin function has R-configuration.	2.06	1	0	amygdalin	antineoplastic agent; apoptosis inducer; plant metabolite
tropisetron hydrochloride [no description available]	2.03	1	0
Reactive blue 2 [no description available]	2.03	1	0	anthraquinone
5,6-dichloro-1-ethyl-1,3-dihydro-2h-benzimidazol-2-one 5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one: stimulates Cl- secretion in the mouse jejunum	2.03	1	0	dichlorobenzene
quinidine sulfate [no description available]	2.03	1	0
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.06	1	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
ipratropium bromide anhydrous [no description available]	2.03	1	0
methamilane methiodide [no description available]	2.03	1	0
pilocarpine nitrate [no description available]	2.03	1	0
r 59949 R 59949: diacylglycerol kinase inhibitor	2.03	1	0	diarylmethane
n(6)-cyclopentyladenosine [no description available]	2.03	1	0
methylatropine nitrate [no description available]	2.03	1	0
sb 366791 N-(3-methoxyphenyl)-4-chlorocinnamanilide: a TRPV1 antagonist; structure in first source	2.03	1	0
ag-213 tyrphostin 47: inhibits protein-tyrosine kinase activity of EGF-R both in vitro and in living cells;	2.03	1	0
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	2.03	1	0	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
bemesetron [no description available]	2.03	1	0
benzoylacrylic acid benzoylacrylic acid: structure in first source	2.05	1	0
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	4.04	2	0
(S)-(-)-pindolol [no description available]	2.03	1	0	pindolol
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.03	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
5-(2-bromovinyl)uracil 5-(2-bromovinyl)uracil: RN given refers to (E)-isomer	3.07	5	0
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.4	2	0	caffeic acid	geroprotector; mouse metabolite
4-fluorophenyl-L-alanine 4-fluorophenyl-L-alanine : A L-phenylalanine derivative that is L-phenylalanine in which the hydrogen at position 4 on the benzene ring is replaced by a fluoro group.	2.03	1	0	4-fluorophenylalanine; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid
urocanic acid Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.	2.03	1	0	urocanic acid	human metabolite
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.03	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
5-iodouridine 5-iodouridine: RN given refers to unlabeled cpd	1.96	1	0
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.03	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.03	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
cysteine sulfinic acid 3-sulfino-L-alanine : The organosulfinic acid arising from oxidation of the sulfhydryl group of L-cysteine.	2.03	1	0	organosulfinic acid; S-substituted L-cysteine	Escherichia coli metabolite; human metabolite; metabotropic glutamate receptor agonist; mouse metabolite
d-ap7 [no description available]	2.03	1	0
4E2RCat [no description available]	4.04	2	0	organic molecular entity
(1R,2S)-tranylcypromine hydrochloride (1R,2S)-tranylcypromine hydrochloride : A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.	2.03	1	0	hydrochloride
tacrine hydrochloride [no description available]	2.03	1	0
4-bromotetramisole, oxalate (1:1), salt(s)-isomer [no description available]	2.03	1	0
3-hydroxybenzylhydrazine hydrochloride [no description available]	2.03	1	0
1-(3-chlorophenyl)biguanide hydrochloride [no description available]	2.03	1	0
4-chlorophenylalanine methyl ester, hydrochloride, (dl)-isomer [no description available]	2.03	1	0
streptozocin [no description available]	2.06	1	0
capsazepine capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.	2.03	1	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
diphenyleneiodium chloride dibenziodolium chloride : An organic chloride salt having dibenziodolium as the counterion.	2.03	1	0	organic chloride salt	EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; G-protein-coupled receptor agonist
azetidine-2,4-dicarboxylic acid, (cis)-isomer [no description available]	2.03	1	0
tamoxifen citrate [no description available]	2.03	1	0	citrate salt	angiogenesis inhibitor; anticoronaviral agent
pimagedine hydrochloride [no description available]	2.03	1	0
Betaine Aldehyde Chloride [no description available]	2.03	1	0	quaternary ammonium salt
eskazine [no description available]	2.03	1	0
monastrol monastrol: stops mitosis by fostering formation of monopolar spindles; structure in first source. (S)-monastrol : An ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate that has S configuration.. monastrol : A racemate comprising equimolar amounts of R- and S-monastrol.. ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate : A member of the class of thioureas that is 3,4-dihydropyrimidine-2(1)-thione substituted by a 3-hydroxyphenyl group at position 4, an ethoxycarbonyl group at position 5, and a methyl group at position 6.	2.03	1	0	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor
at 61 AT 61: a phenylpropenamide derivative; structure in first source	2.05	1	0
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	2.06	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
thiocarlide thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent	2.04	1	0	thioureas
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.03	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine: a highly active anti-HIV agent; structure in first source	2.05	1	0
vicriviroc vicriviroc: structure in first source	2.05	1	0	(trifluoromethyl)benzenes
hcv 371 [no description available]	2.05	1	0
4-diphenylacetoxy-n-methylpiperidine methiodide 4-DAMP methiodide : A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane.	2.03	1	0	iodide salt; quaternary ammonium salt	cholinergic antagonist; muscarinic antagonist
thiouridine Thiouridine: A photoactivable URIDINE analog that is used as an affinity label.. 4-thiouridine : A thiouridine in which the oxygen replaced by sulfur is that at C-4.	1.98	1	0	nucleoside analogue; thiouridine	affinity label; antimetabolite
quinine [no description available]	2.07	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
1-(4-hydroxybenzyl)imidazole-2-thiol 1-(4-hydroxybenzyl)imidazole-2-thiol: RN & structure given in first source; RN not in Chemline 3/87	2.03	1	0
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	2.03	1	0
bp 897 BP 897: a dopamine D3 receptor agonist; structure in first source	2.03	1	0	naphthalenecarboxamide
trequinsin hydrochloride [no description available]	2.03	1	0
neboglamine neboglamine: potential memory enhancer	2.03	1	0
benzatropine methanesulfonate benzatropine mesylate : The methanesulfonate salt of benzatropine. An acetylcholine receptor antagonist, it is used in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	2.03	1	0
sb 203186 [no description available]	2.03	1	0	indolyl carboxylic acid
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a 5-HT(2B) receptor antagonist; structure given in first source. 1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea : A member of ther class of ureas that is urea in which a hydrogen attached to one of the nitrogens has been replaced by an N-methylindol-5-yl group, while a hydrogen attached to the other nitrogen has been replaced by a 3-methyl-1,2-thiazol-5-yl group. It is a potent and selective antagonist for the 5-hydroxytryptamine 2B (5-HT2B) receptor.	2.03	1	0	1,2-thiazoles; indoles; ureas	receptor modulator; serotonergic antagonist
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.03	1	0	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
ro 41-0960 [no description available]	2.03	1	0
cgp 13501 CGP 13501: structure in first source	2.03	1	0	alkylbenzene
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide N-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide: dopamine D4 ligand; structure in first source	2.03	1	0
brl 15572 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol : An N-alkylpiperazine that is 1-(3-chlorophenyl)piperazine carrying a 3,3-diphenyl-2-hydroxyprop-1-yl group at position 4. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.	2.03	1	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; secondary alcohol	geroprotector; serotonergic antagonist
mrs 1523 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate: adenosine A3 receptor antagonist	2.03	1	0
or486 OR486: structure given in first source	2.03	1	0
fg 9041 FG 9041: structure given in first source	2.03	1	0	quinoxaline derivative
iik7 IIK7: structure in first source	2.03	1	0
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
dm 235 DM 235: structure in first source	2.03	1	0
jhw 015 [no description available]	2.03	1	0	indolecarboxamide
bw 723c86 [no description available]	2.03	1	0	tryptamines
sc 560 SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.	2.03	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
sc-19220 [no description available]	2.03	1	0	aromatic ether
le 300 [no description available]	2.03	1	0	indoles
ly 367265 LY 367265: a 5-hydroxytryptamine transporter inhibitor; a 5-HT(2A) receptor antagonist; structure in first source. LY-367,265 : A fluoroindole that is 1H-indole in which the hydrogens at positions 3 and 6 are replaced by 1-[2-(2,2-dioxo-5,6-dihydro-4H-2lambda(6)-[1,2,5]thiadiazolo[4,3,2-ij]quinolin-1(2H)-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl and fluoro groups, respectively. It is an inhibitor of the 5-hydroxytryptamine transporter (Ki = 2.3 nM) and an antagonist of 5-hydroxytryptamine(2A) receptor (Ki = 0.81 nM).	2.03	1	0	dihydropyridine; fluoroindole; tertiary amino compound; thiadiazoloquinoline	antidepressant; geroprotector; serotonergic antagonist; serotonin uptake inhibitor
diclofenac sodium Diclofenac Sodium: The sodium form of DICLOFENAC. It is used for its analgesic and anti-inflammatory properties.. diclofenac sodium : The sodium salt of diclofenac.	2.03	1	0	organic sodium salt
cgp 7930 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol: structure in first source	2.03	1	0	alkylbenzene
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole 4,4',4''-(4-propylpyrazole-1,3,5-triyl)trisphenol : A pyrazole that is 1H-pyrazole bearing three 4-hydroxyphenyl substituents at positions 1, 3 and 5 as well as a propyl substituent at position 4. Potent, subtype-selective estrogen receptor agonist (EC50 ~ 200 pM); displays 410-fold selectivity for ERalpha over ERbeta. Prevents ovariectomy-induced weight gain and loss of bone mineral density, and induces gene expression in the hypothalamus following systemic administration in vivo.	2.03	1	0	phenols; pyrazoles	estrogen receptor agonist
sib 1757 SIB 1757: a selective mGluR5 antagonist; structure in first source	2.03	1	0
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.03	1	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	4.04	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	2.05	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.03	1	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.03	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
daphnetin [no description available]	2.03	1	0	hydroxycoumarin
genistein [no description available]	2.03	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.06	1	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.03	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
timolol maleate (S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid.	2.03	1	0	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.03	1	0	maleate salt	anti-allergic agent
chlorpheniramine maleate [no description available]	2.03	1	0	organic molecular entity
clemastine fumarate clemastine fumarate : The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	2.03	1	0	fumarate salt	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
methylergonovine maleate [no description available]	2.03	1	0	ergoline alkaloid	geroprotector
astaxanthine astaxanthine: a keto form of carotene; pigment in flesh of Scottish salmon (Salmo salar) crustacoa-lobster (Homarus gammarus, flamingo feathers; structure; a carotenoid without vitamin A activity, has shown anti-oxidant and anti-inflammatory activities. astaxanthin : A carotenone that consists of beta,beta-carotene-4,4'-dione bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'S diastereomer). A carotenoid pigment found mainly in animals (crustaceans, echinoderms) but also occurring in plants. It can occur free (as a red pigment), as an ester, or as a blue, brown or green chromoprotein.	2.03	1	0	carotenol; carotenone	animal metabolite; anticoagulant; antioxidant; food colouring; plant metabolite
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	0	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.03	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin [no description available]	2.03	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
daidzein [no description available]	2.03	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.03	1	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.03	1	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
flupenthixol cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.	2.03	1	0	flupenthixol	dopaminergic antagonist
n-oleoyldopamine N-oleoyldopamine: putative capsaicin receptor ligand; produces hyperalgesia; isolated from the brain. N-oleoyldopamine : A fatty amide resulting from the formal condensation of the carboxy group of oleic acid with the amino group of dopamine. Synthesised in catecholaminergic neurons, it crosses the blood-brain barrier and might be considered as a carrier of dopamine into the brain. It is a transient receptor potential vanilloid type 1 (TRPV1) receptor agonist.	2.03	1	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide	TRPV1 agonist
pheniramine maleate Naphcon A: tradename; contains above compounds; ophthalmic solution	2.03	1	0	organic molecular entity
sorivudine [no description available]	5.54	13	0	organic molecular entity
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.03	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
trimipramine maleate [no description available]	2.03	1	0	maleate salt	antidepressant
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	2.03	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
xylometazoline hydrochloride [no description available]	2.03	1	0
flunarizine hydrochloride [no description available]	2.03	1	0	diarylmethane
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.03	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
cis-flupenthixol dihydrochloride cis-flupenthixol dihydrochloride : The dihydrochloride salt of cis-flupenthixol.	2.03	1	0	hydrochloride	geroprotector
n-arachidonylglycine N-arachidonylglycine: structure in first source. N-arachidonoylglycine : Biologically active derivative of anandamide	2.03	1	0	fatty amide; N-acylglycine
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.03	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
codeine [no description available]	2.06	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.03	1	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
phenoxybenzamine hydrochloride [no description available]	2.03	1	0	organic molecular entity
phenylephrine hydrochloride Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.. phenylephrine hydrochloride : A hydrochloride that is the monohydrochloride salt of phenylephrine.	2.03	1	0	hydrochloride
mepyramine maleate histosol: proprietary mixture of synthetic aromatic hydrocarbons forming an extremely nonpolar organic solvent	2.03	1	0
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	2.06	1	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	4.04	2	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
brefeldin a [no description available]	2.03	1	0	macrolide antibiotic	Penicillium metabolite
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.03	1	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid: RN refers to (E)-isomer; structure given in first source. arotinoid acid : A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR).	2.03	1	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent; retinoic acid receptor agonist; teratogenic agent
l-2-(carboxypropyl)glycine [no description available]	2.03	1	0
4-aminocrotonic acid [no description available]	2.03	1	0
denopamine denopamine: structure given in first source	2.03	1	0	dimethoxybenzene
l 655,708 [no description available]	2.03	1	0
ro 41-1049 Ro 41-1049: structure given in first source	2.03	1	0
sb 200646a [no description available]	2.03	1	0
seglitide seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist	2.03	1	0
sib 1893 SIB 1893: a selective mGluR5 antagonist; structure in first source	2.03	1	0
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.03	1	0
tyrphostin ag 555 [no description available]	2.03	1	0
tyrphostin ag-494 AG 494: tyrphostin that blocks Cdk2 activation; structure in first source	2.03	1	0
tyrphostin b44 tyrphostin B44: inhibits protein kinases; an analog of tyrphostin B46; B44(+) is B50, and is the stereoisomer of B44(-)	2.03	1	0
ag-490 [no description available]	2.03	1	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
ag 112 [no description available]	2.03	1	0
ag 183 AG 183: structure given in first source	2.03	1	0
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.03	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
8-(3-chlorostyryl)caffeine 8-(3-chlorostyryl)caffeine: adenosine antagonist. 8-(3-chlorostyryl)caffeine : Caffeine substituted at its 8-position by an (E)-3-chlorostyryl group.	2.03	1	0	monochlorobenzenes; trimethylxanthine	adenosine A2A receptor antagonist; EC 1.4.3.4 (monoamine oxidase) inhibitor
bay 11-7085 BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB.	2.03	1	0	benzenes; nitrile; sulfone	anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor
molsidomine [no description available]	2.03	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
diamide Diamide: A sulfhydryl reagent which oxidizes sulfhydryl groups to the disulfide form. It is a radiation-sensitizing agent of anoxic bacterial and mammalian cells.	2.03	1	0	1,1'-azobis(N,N-dimethylformamide)
nomifensine maleate [no description available]	2.03	1	0
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	4.04	2	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
nalbuphine hydrochloride [no description available]	2.03	1	0	hydrochloride
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.06	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	4.23	3	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	2.06	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	2.06	1	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
isoalloxazine isoalloxazine: structure	2.03	1	0	benzo[g]pteridine-2,4-dione
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.06	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
vinblastine sulfate [no description available]	2.03	1	0
n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.	2.03	1	0
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	1.97	1	0	cysteinium	fundamental metabolite
dextromethorphan hydrobromide dextromethorphan hydrobromide : The hydrobromide and monohydrate of the antitussive drug dextromethorphan.	2.03	1	0	hydrate; hydrobromide
naloxone hydrochloride naloxone hydrochloride : A hydrochloride resulting from the formal reaction of equimolar amounts of naloxone and hydrogen chloride. A specific opioid antagonist, it is used to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.03	1	0	hydrochloride	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
s-trans,trans-farnesylthiosalicylic acid farnesylthiosalicylic acid: structure in first source	2.03	1	0	sesquiterpenoid
sulindac sulfone sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source. sulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.	2.03	1	0	monocarboxylic acid; organofluorine compound; sulfone	apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	4.04	2	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
cefuroxime [no description available]	2.06	1	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	2.06	1	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	2.06	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
naltrexone hydrochloride naltrexone hydrochloride : A hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. it is a mu-opioid receptor antagonist that is used to treat alcohol dependence.	2.03	1	0	hydrochloride	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxyfedrine Oxyfedrine: A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.	2.06	1	0	aromatic ketone
bms 806 BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002	2.05	1	0
guanabenz acetate [no description available]	2.03	1	0	dichlorobenzene	geroprotector
guanabenz Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.	2.06	1	0	dichlorobenzene
nylidrin hydrochloride [no description available]	2.03	1	0	alkylbenzene
triprolidine hydrochloride anhydrous triprolidine hydrochloride (anh.) : A hydrochloride resulting from the formal reaction of equimolar amounts of triprolidine and hydrogen chloride. Its monohydrate is used for the symptomatic relief of uticaria, rhinitis, and various pruritic skin disorders.	2.03	1	0	hydrochloride	H1-receptor antagonist
famotidine [no description available]	2.45	2	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.03	1	0	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
tiapridex Tiapride Hydrochloride: A benzamide derivative that is used as a dopamine antagonist.	2.03	1	0	benzamides
quipazine maleate [no description available]	2.03	1	0
n-(2-aminoethyl)-4-chlorobenzamide hydrochloride Ro 16-6491: structure given in first source	2.03	1	0
tulobuterol hydrochloride [no description available]	2.03	1	0	organic molecular entity
hp 029 [no description available]	2.03	1	0
aztreonam [no description available]	2.06	1	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
n,n,n-trimethyl-1-(4-stilbenoxy)-2-propylammonium iodide [no description available]	2.03	1	0
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one: structure given in first source; potent irreversible, mechanism-based inhibitor of myocardial calcium-independent phospholipase A2	2.03	1	0	naphthalenes
nf023 [no description available]	2.03	1	0
nf 449 [no description available]	2.03	1	0
7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine [no description available]	2.03	1	0
gr 46611 GR 46611: known to lower body temperature in guinea pigs	2.03	1	0
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.15	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
diacetylmonoxime diacetylmonoxime: used diagnostically for determining urea in blood; structure; myosin ATPase antagonist. diacetylmonoxime : A ketoxime obtained via formal condensation of butane-2,3-dione with hydroxylamine. It is a reversible myosin ATPase inhibitor.	2.03	1	0
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.06	1	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
homatropine hydrobromide, (endo-(+-)-isomer) [no description available]	2.03	1	0
vancomycin hydrochloride [no description available]	2.03	1	0
moxisylyte hydrochloride [no description available]	2.03	1	0	monoterpenoid
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.03	1	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
beta-aminopropionitrile fumarate beta-aminopropionitrile fumarate: RN given refers to unspecified fumarate	2.03	1	0
flupirtine [no description available]	2.03	1	0
zimelidine hydrochloride [no description available]	2.03	1	0
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	4.04	2	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
dioleoyl phosphatidylethanolamine dioleoyl phosphatidylethanolamine: chemical name in article is incorrect - phosphatidylethandamine instead of phosphatidylethanolamine. dioleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups are both oleoyl.	2.01	1	0	phosphatidylethanolamine
5-(2-iodovinyl)-2'-deoxyuridine 5-(2-iodovinyl)-2'-deoxyuridine: RN given refers to cpd without isomeric designation	3.67	10	0
5-(2-bromovinyl)-2'-deoxyuridine-5'-triphosphate [no description available]	1.96	1	0
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1h,3h)-pyrimidinedione 1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1H,3H)-pyrimidinedione: RN & structure given in first source; RN refers to (E)-isomer	1.96	1	0
5-(1-propenyl)-2'-deoxyuridine 5-(1-propenyl)-2'-deoxyuridine: has anti-herpes activity; structure in first source	2.65	3	0
5-(2-iodovinyl)-2'-deoxyuridine [no description available]	2.4	2	0
flutimide flutimide: isolated from Delitschia confertaspora; selectively inhibits the transcriptase of influenza viruses; structure given	2.05	1	0
5-(2-iodovinyl)-1-(2'-fluoro-2'-deoxyuridine) 5-(2-iodovinyl)-1-(2'-fluoro-2'-deoxyuridine): structure given in first source	2.37	2	0
pregna-4,17-diene-3,16-dione, (17z)-isomer [no description available]	2.03	1	0
su 4312 SU4312 : A member of the class of oxindoles that is 3-methyleneoxindole in which one of the hydrogens of the methylene group has been replaced by a p-(dimethylamino)phenyl group. SU 4312 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 and platelet derived growth factor (PDGF) receptor inhibitor. It also inhibits the neuronal nitric oxide synthase (NOS) and exhibits neuroprotection against NO-mediated neurotoxicity.	2.03	1	0
a 315675 [no description available]	2.05	1	0
rilpivirine [no description available]	2.05	1	0	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
bms 433771 [no description available]	2.05	1	0
5-(2-bromovinyl)uridine 5-(2-bromovinyl)uridine: structure given in first source	2.67	3	0
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	2.06	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
5-(2-bromovinyl)-2'-deoxyuridylate 5-(2-bromovinyl)-2'-deoxyuridylate: RN given refers to cpd without isomeric designation	1.96	1	0
gw 1929 GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first source	2.03	1	0	benzophenones
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.06	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
protriptyline hydrochloride [no description available]	2.03	1	0	hydrochloride	antidepressant
n(4)-chloroacetylcytosine arabinoside [no description available]	2.03	1	0
n-(3-(cyclohexylidene-(1h-imidazol-4-ylmethyl))phenyl)ethanesulfonamide [no description available]	2.03	1	0
n-(4-amino-2-chlorophenyl)phthalimide N-(4-amino-2-chlorophenyl)phthalimide: has anticonvulsant activity; structure in first source	2.03	1	0
cb 34 CB 34: ligand for peripheral benzodiazepine receptors; structure in first source	2.03	1	0
b 43 RK-24466 : A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively).	2.03	1	0	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol [no description available]	2.03	1	0	aporphine alkaloid
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol [no description available]	2.03	1	0	aporphine alkaloid
3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane 3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane: structure in first source	2.03	1	0
2-(3,3-diphenylpropylamino)acetamide [no description available]	2.03	1	0	diarylmethane
4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide 4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide: structure given in first source	2.03	1	0
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	2.03	1	0	pyridopyrimidine
l 162313 L 162313: a biphenylimidazole derivative; a non-peptide angiotensin agonist; no further information available 2/95	2.03	1	0
l-165041 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.	2.03	1	0	aromatic ketone
mrs 1754 [no description available]	2.03	1	0	oxopurine
s-nitroso-n-acetylpenicillamine S-Nitroso-N-Acetylpenicillamine: A sulfur-containing alkyl thionitrite that is one of the NITRIC OXIDE DONORS.	2.03	1	0	nitroso compound; nitrosothio compound	nitric oxide donor; vasodilator agent
pd 404182 [no description available]	2.03	1	0
sb 222200 [no description available]	2.03	1	0	quinolines
dantrolene sodium dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.	2.03	1	0
cr 2945 CR 2945: a member of non-peptide CCKB receptor antagonist	2.03	1	0
sb 218795 SB 218795: structure in first source	2.03	1	0	quinolines
dihydroceramide N-acetylsphinganine : A dihydroceramide in which the ceramide acyl group is specified as acetyl.	2.03	1	0	N-acylsphinganine
epinephrine bitartrate [no description available]	2.03	1	0
bicuculline methobromide [no description available]	2.03	1	0
butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.	2.03	1	0
butaclamol hydrochloride [no description available]	2.03	1	0
a 38503 [no description available]	2.03	1	0
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide [no description available]	2.03	1	0
sk&f 89976-a [no description available]	2.03	1	0
cv 1808 2-phenylaminoadenosine: has coronary & cardiohemodynamic effects	2.03	1	0	purine nucleoside
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.48	2	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone [no description available]	4.04	2	0	oligopeptide
fluvoxamine maleate [no description available]	2.03	1	0	(trifluoromethyl)benzenes
gs-7340 tenofovir alafenamide: component of Biktarvy. tenofovir alafenamide : An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection.	2.15	1	0	6-aminopurines; ether; isopropyl ester; L-alanine derivative; phosphoramidate ester	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
naloxone benzoylhydrazone [no description available]	2.03	1	0
2-methyl-6-(phenylethynyl)pyridine hydrochloride 2-methyl-6-(phenylethynyl)pyridine hydrochloride : A hydrochloride salt obtained by reaction of 2-methyl-6-(phenylethynyl)pyridine with one equivalent of hydrochloric acid. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.03	1	0	hydrochloride	anxiolytic drug; metabotropic glutamate receptor antagonist
amiprilose [no description available]	2.03	1	0
(R)-fluoxetine hydrochloride (R)-fluoxetine hydrochloride : A hydrochloride obtained by reaction of (R)-fluoxetine with one equivalent of hydrochloric acid.	2.03	1	0	hydrochloride	antidepressant; serotonin uptake inhibitor
pd 144418 [no description available]	4.04	2	0
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	4.04	2	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
lu 28-179 Lu 28-179: sigma(2) ligand and lysosomotropic agent; structure in first source	4.04	2	0
gentamicin sulfate [no description available]	2.05	1	0
desmethylselegiline hydrochloride [no description available]	2.03	1	0
3-morpholino-sydnonimine monohydrochloride [no description available]	2.03	1	0
t 1032 T 1032: a cyclic GMP phosphodiesterase-5 inhibitor; structure in first source	2.03	1	0
qx-314 bromide [no description available]	2.03	1	0
(S)-fluoxetine hydrochloride (S)-fluoxetine hydrochloride : A hydrochloride obtained by reaction of (S)-fluoxetine with one equivalent of hydrochloric acid.	2.03	1	0	hydrochloride	antidepressant; serotonin uptake inhibitor
sr 59230a 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate: structure given in first source	2.03	1	0
u 74389g [no description available]	2.03	1	0
gentamicin sulfate [no description available]	2.06	1	0
1-(2-methoxyphenyl)piperazine hydrochloride [no description available]	2.03	1	0
y 27632, dihydrochloride, (4(r)-trans)-isomer [no description available]	2.03	1	0
noscapine hydrochloride [no description available]	2.03	1	0
a 77636 (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride : A hydrochloride salt obtained by mixing equimolar amounts of (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol with hydrochloric acid. Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.	2.03	1	0	hydrochloride	antiparkinson drug; dopamine agonist
cgp 20712a CGP 20712A: structure given in first source; CGP 26505, a beta1-selective beta-adrenoceptor antagonist, is the (S)-isomer of CGP 20712A	2.03	1	0
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	4.04	2	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
levodopa methyl ester hydrochloride [no description available]	2.03	1	0
benalfocin hydrochloride [no description available]	2.03	1	0
lu 19005 [no description available]	2.03	1	0
benoxathian hydrochloride [no description available]	2.03	1	0
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid, (+)-isomer [no description available]	2.03	1	0
n-cyclopropyl adenosine-5'-carboxamide [no description available]	2.03	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	4.04	2	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
cefotaxime sodium [no description available]	2.03	1	0	organic sodium salt
4'-thiothymidine 4'-thiothymidine: RN & structure given in first source	1.97	1	0
calpain inhibitor iii calpain inhibitor III: potential anticataract drug	2.03	1	0
GR 127935 hydrochloride GR 127935 hydrochloride : A hydrochloride obtained by reaction of GR 127935 with one equivalent of hydrochloric acid. Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration.	2.03	1	0	hydrochloride	serotonergic antagonist
mrs 1845 [no description available]	2.03	1	0
at 13387 (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone: structure in first source. onalespib : A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.	4.04	2	0	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor
1-aminocyclopropane-1-carboxylic acid hydrochloride [no description available]	2.03	1	0
alaproclate hydrochloride [no description available]	2.03	1	0
ubenimex [no description available]	2.03	1	0	peptide
3-chloroalanine hydrochloride, (l-ala)-isomer [no description available]	2.03	1	0
dsp 4 hydrochloride [no description available]	2.03	1	0
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	2.03	1	0	benzoxazole
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine hydrochloride : A hydrochloride salt that is obtained by reaction of N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine with one equivalent of hydrogen chloride. An alpha1A-adrenergic selective antagonist.	2.03	1	0	hydrochloride	alpha-adrenergic antagonist
2-cyclooctyl-2-hydroxyethylamine hydrochloride [no description available]	2.03	1	0
cirazoline monohydrochloride [no description available]	2.03	1	0
adtn [no description available]	2.03	1	0
apocodeine hydrochloride, (r)-isomer [no description available]	2.03	1	0
Dihydro-beta-erythroidine hydrobromide [no description available]	2.03	1	0	indoles
lilly 78335 [no description available]	2.03	1	0
efaroxan hydrochloride [no description available]	2.03	1	0
fenoldopam hydrobromide [no description available]	2.03	1	0
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride : A hydrochloride salt that is obtained by reaction of 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine with two equivalents of hydrogen chloride. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).	2.03	1	0	hydrochloride	dopamine uptake inhibitor
guvacine hydrochloride [no description available]	2.03	1	0
7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide [no description available]	2.03	1	0
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer, [no description available]	2.03	1	0	organic molecular entity
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one LY-310762 hydrochloride : A hydrochloride resulting from the formal reation of equimolar amount of LY-310762 with hydrogen chloride. A potent and selective antagonist for the 5-hydroxytryptamine 1D (5-HT1D) receptor.	2.03	1	0	hydrochloride	receptor modulator; serotonergic antagonist
4-iodoclonidine [no description available]	2.03	1	0
4-methylpyrazole monohydrochloride [no description available]	2.03	1	0
tele-methylhistamine [no description available]	2.03	1	0
alpha-methyltyrosine methyl ester, monohydrochloride [no description available]	2.03	1	0
octoclothepine maleate [no description available]	2.03	1	0
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride [no description available]	2.03	1	0
du 24565 [no description available]	2.03	1	0
2-methoxyidazoxan hydrochloride [no description available]	2.03	1	0
ro 25-6981 [no description available]	2.03	1	0
sk&f 77434 N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide : A hydrobromide salt prepared from N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.	2.03	1	0	hydrobromide	dopamine agonist; prodrug
3-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea [no description available]	2.03	1	0	organic heterotetracyclic compound; organonitrogen heterocyclic compound
arabinofuranosyluracil Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.	5.84	18	0
demethylcantharidin demethylcantharidin: has antineoplastic activity; structure in first source	2.03	1	0
atropine sulfate [no description available]	2.03	1	0
1-deoxynojirimycin hydrochloride [no description available]	2.03	1	0
tetrahydrouridine Tetrahydrouridine: An inhibitor of nucleotide metabolism.	1.97	1	0
win 62577 [no description available]	2.03	1	0
Benzotriazol-1-yl 1H-indole-5-carboxylate [no description available]	2.17	1	0	indolyl carboxylic acid	anticoronaviral agent
oligonucleotides [no description available]	3.12	1	0
quinine sulfate [no description available]	2.03	1	0	hydrate
quercetin [no description available]	2.03	1	0
rv 538, (r-(r,r))-isomer [no description available]	2.03	1	0
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1s-cis)-isomer [no description available]	2.03	1	0
valproate sodium Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.	2.03	1	0	organic sodium salt	geroprotector
lucifer yellow lucifer yellow: RN given refers to di-Li salt	2.06	1	0	organic lithium salt	fluorochrome
u 63557a [no description available]	2.03	1	0
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
taurocholic acid, monosodium salt [no description available]	2.03	1	0	bile salt
cefmetazole sodium cefmetazole sodium : An organic sodium salt that is the sodium salt of cefmetazole.	2.03	1	0	organic sodium salt	antimicrobial agent
fusidate sodium [no description available]	2.03	1	0
cephapirin sodium cephapirin sodium : The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.	2.03	1	0	cephalosporin; organic sodium salt	antibacterial drug
sodium cephalothin [no description available]	2.03	1	0	organic sodium salt
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.03	1	0	organic sodium salt
5-hydroxydecanoic acid, monosodium salt [no description available]	2.03	1	0
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	2.03	1	0
phenytoin sodium [no description available]	2.03	1	0
cr 1409 lorglumide sodium : A racemate comprising equal amounts of (R)- and (S)-lorglumide sodium.	2.03	1	0
cortisol succinate, sodium salt hydrocortisone hemisuccinate: RN given refers to (11beta)-isomer; Synonyms Solu-Cortef & sopolcort H refer to Na salt	2.03	1	0	organic molecular entity
cx 4945 [no description available]	4.04	2	0
ponatinib [no description available]	4.04	2	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
incb-018424 [no description available]	4.04	2	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
e-52862 [no description available]	4.04	2	0
letermovir letermovir: has antiviral activity; structure in first source	2.11	1	0
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine sapanisertib: an mTOR inhibitor	4.04	2	0	benzoxazole
jq1 compound [no description available]	4.04	2	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
ML240 ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP).	4.04	2	0	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.21	1	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.06	1	0
piroxicam [no description available]	2.03	1	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	2.03	1	0	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.06	1	0	benzenes; hydroxycoumarin; methyl ketone
l 701324 L 701324: a glycine/NMDA receptor antagonist	2.03	1	0	quinolines
hispidin hispidin: metabolite of Basidiomycete Polyporus hispidus. hispidin : Fungal metabolite first found in basidiomycete Inonotus hispidus (formerly Polyporus hispidus).	2.03	1	0	2-pyranones; catechols	antioxidant; EC 2.7.11.13 (protein kinase C) inhibitor; fungal metabolite
minocycline hydrochloride [no description available]	2.03	1	0
demeclocycline hydrochloride demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	2.03	1	0
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	4.04	2	0	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
PF-06446846 PF-06446846: inhibits translation of PCSK9 ;structure in first source. PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9.	4.04	2	0	benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine	antilipemic drug; EC 3.4.21.61 (kexin) inhibitor
s 8932 [no description available]	2.31	1	0	aromatic amine; C-nucleoside; carboxylic ester; nitrile; phosphoramidate ester; pyrrolotriazine	anticoronaviral agent; antiviral drug; prodrug
dBET6 [no description available]	4.04	2	0	organic molecular entity
MZ1 [no description available]	4.04	2	0	organic molecular entity
AZ3451 [no description available]	4.04	2	0	benzimidazoles; benzodioxoles; nitrile; organobromine compound; secondary carboxamide	anti-inflammatory agent; autophagy inducer; PAR2 negative allosteric modulator
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.15	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	20.08	214	7	2-aminopurines; oxopurine	antimetabolite; antiviral drug
sepiapterin sepiapterin: A substrate of sepiapterin reductase	2.03	1	0	sepiapterin
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.4	2	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	8.45	24	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
isoxanthopterin [no description available]	2.03	1	0	dihydroxypteridine
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.03	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.42	2	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	13.78	114	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	9.62	12	1	L-valyl ester	antiviral drug
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	4.04	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	5.66	14	0	2-aminopurines; propane-1,3-diols	antiviral drug
zaprinast zaprinast: anaphylaxis inhibitor; structure	2.03	1	0	triazolopyrimidines
raltitrexed [no description available]	2	1	0	N-acyl-amino acid
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.03	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	2.03	1	0
acyclovir triphosphate [no description available]	1.96	1	0
2,4-diaminohypoxanthine 2,4-diaminohypoxanthine: do not confuse abbreviation DAHP with various dehydro-deoxy-arabino-heptulosonic acid phosphates which also use DAHP; RN given refers to parent cpd; structure	2.03	1	0	hydroxypyrimidine
cyclopropavir cyclopropavir: cyclopropavir is the (Z)-isomer; has antiviral activity; structure in first source	2.05	1	0
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	2.06	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
9-((2-phosphonylmethoxy)ethyl)guanine 9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source	2.03	1	0	phosphoethanolamine
buciclovir buciclovir: structure given in first source	3.06	1	0
lobucavir lobucavir: inhibits the replication of HIV virus in T cells, monocytes & macrophages in vitro by inhibiting DNA polymerase and viral DNA synthesis	3.08	1	0
valganciclovir Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.	3.13	1	0	L-valyl ester; purines	antiviral drug; prodrug
quazinone [no description available]	2.03	1	0
8-bromocyclic gmp, sodium salt sodium 8-bromo-3',5'-cyclic GMP : An organic sodium salt having 8-bromoguanosine 3',5'-cyclic phosphate as the counterion. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.	2.03	1	0	organic sodium salt	muscle relaxant; protein kinase G agonist
ag-879 AG-879: structure given in first source	2.03	1	0
9-(4-hydroxybutyl)guanine [no description available]	2.49	2	0
n(2)-(3-trifluoromethylphenyl)guanine [no description available]	2.03	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	4.04	2	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	4.04	2	0
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	1.96	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	0	6.3	36	0
Leukemia L 1210 [description not available]	0	3.58	9	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	0	2.67	3	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	3.11	5	0
Viral Diseases [description not available]	0	6.87	6	2
HIV Coinfection [description not available]	0	1.97	1	0
Virus Diseases A general term for diseases caused by viruses.	1	8.87	6	2
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	1.97	1	0
Herpes Simplex Virus Infection [description not available]	0	9.71	56	2
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	0	9.71	56	2
Experimental Neoplasms [description not available]	0	2.66	3	0
Herpes Simplex Keratitis [description not available]	0	5.38	5	1
Keratitis, Herpetic A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (KERATITIS, DENDRITIC). (Dictionary of Visual Science, 3d ed)	0	5.38	5	1
Experimental Mammary Neoplasms [description not available]	0	3.07	5	0
EBV Infections [description not available]	0	2.03	1	0
B Virus Infection [description not available]	0	8.43	21	1
B-Cell Lymphoma [description not available]	0	2.03	1	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	2.03	1	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	2.03	1	0
Benign Neoplasms [description not available]	0	6.86	11	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	6.86	11	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.92	4	0
Cytomegalic Inclusion Disease [description not available]	0	6.7	7	1
Shingles [description not available]	0	13.49	50	7
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	0	6.7	7	1
Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)	0	18.49	50	7
Anemia, Fanconi [description not available]	0	2.13	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	0	2.13	1	0
Congenital Varicella Syndrome [description not available]	0	2.63	2	0
Genital Herpes [description not available]	0	6.14	7	1
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	0	6.14	7	1
Infections, Coronavirus [description not available]	0	5.11	4	0
2019 Novel Coronavirus Disease [description not available]	0	5.11	4	0
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	0	5.11	4	0
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	0	5.11	4	0
Keloid A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues.	0	2.17	1	0
Chickungunya Fever [description not available]	0	3.09	1	0
Congenital Zika Syndrome [description not available]	0	3.09	1	0
Measles, German [description not available]	0	3.09	1	0
Herpes Zoster, Ocular [description not available]	0	5.9	9	1
Eye Infections, Viral Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus.	0	3.09	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	3.09	1	0
Herpes Zoster Ophthalmicus Virus infection of the Gasserian ganglion and its nerve branches characterized by pain and vesicular eruptions with much swelling. Ocular involvement is usually heralded by a vesicle on the tip of the nose. This area is innervated by the nasociliary nerve.	0	5.9	9	1
Uveitis, Anterior Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.	0	3.34	2	0
Brachial Paresis [description not available]	0	2.21	1	0
Impairment, Light Touch Sensation [description not available]	0	2.08	1	0
Postherpetic Neuralgia [description not available]	0	5.74	4	1
Allodynia [description not available]	0	2.08	1	0
Dyskinesia Syndromes [description not available]	0	2.08	1	0
Infectious Myelitis [description not available]	0	2.08	1	0
Athetoid Movements [description not available]	0	2.08	1	0
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	0	2.08	1	0
Neuralgia, Postherpetic Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.	0	5.74	4	1
Chicken Pox [description not available]	0	6.25	8	1
Chickenpox A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)	0	6.25	8	1
Coronary Artery Vasospasm [description not available]	0	2.11	1	0
Symptom Cluster [description not available]	0	2.11	1	0
Coronary Vasospasm Spasm of the large- or medium-sized coronary arteries.	0	7.11	1	0
Syndrome A characteristic symptom complex.	0	7.11	1	0
Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.	0	2.15	1	0
Autoimmune Disease [description not available]	0	2.15	1	0
Alloxan Diabetes [description not available]	0	2.15	1	0
Autoimmune Diabetes [description not available]	0	2.15	1	0
Allergic Encephalomyelitis [description not available]	0	2.15	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	2.15	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	0	2.15	1	0
EHS Tumor [description not available]	0	2.04	1	0
Facial Palsy [description not available]	0	2.04	1	0
Central Nervous System Origin Vertigo [description not available]	0	2.04	1	0
Emesis [description not available]	0	2.04	1	0
Auricular Syndrome of Ramsay Hunt [description not available]	0	2.43	2	0
Vertigo An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)	0	2.04	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	2.04	1	0
Adverse Drug Event [description not available]	0	2.39	2	0
Colorectal Cancer [description not available]	0	2.73	3	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1	4.73	3	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.39	2	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.4	2	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.4	2	0
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	0	2.97	1	0
Anemia, Hypoplastic [description not available]	0	2.97	1	0
Breast Cancer [description not available]	0	4.32	7	0
Peripheral Nerve Diseases [description not available]	0	2.97	1	0
Mucositis, Oral [description not available]	0	2.97	1	0
Tooth Discoloration Any change in the hue, color, or translucency of a tooth due to any cause. Restorative filling materials, drugs (both topical and systemic), pulpal necrosis, or hemorrhage may be responsible. (Jablonski, Dictionary of Dentistry, 1992, p253)	0	2.97	1	0
Onycholysis Separation of nail plate from the underlying nail bed. It can be a sign of skin disease, infection (such as ONYCHOMYCOSIS) or tissue injury.	0	2.97	1	0
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	0	2.97	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	4.32	7	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	2.97	1	0
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	0	2.97	1	0
Encephalitis, Viral Inflammation of brain parenchymal tissue as a result of viral infection. Encephalitis may occur as primary or secondary manifestation of TOGAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; BUNYAVIRIDAE INFECTIONS; PICORNAVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RETROVIRIDAE INFECTIONS; and ARENAVIRIDAE INFECTIONS.	0	3.34	2	0
Allergic Cutaneous Angiitis [description not available]	0	2.05	1	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	2.05	1	0
Cancer of Esophagus [description not available]	0	2.05	1	0
Exanthem [description not available]	0	2.05	1	0
Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.	0	2.05	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	2.05	1	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	2.05	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	0	2.05	1	0
Adenocarcinoma, Basal Cell [description not available]	0	5.89	9	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	6.59	7	1
Cancer of Pancreas [description not available]	0	5.24	4	1
Sarcoma, Epithelioid [description not available]	0	4.37	1	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	5.89	9	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	1	7.24	4	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	4.37	1	1
Eperythrozoonosis [description not available]	0	2.07	1	0
Cancer of Stomach [description not available]	0	2.42	2	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.42	2	0
Encephalopathy, Toxic [description not available]	0	2.07	1	0
Delirium of Mixed Origin [description not available]	0	2.07	1	0
Delirium A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)	0	2.07	1	0
Anasarca [description not available]	0	2.07	1	0
Abdominal Migraine [description not available]	0	2.07	1	0
Eyelid Diseases Diseases involving the EYELIDS.	0	2.07	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	2.07	1	0
Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	0	2.07	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.01	1	0
Bone Marrow Diseases Diseases involving the BONE MARROW.	0	2.01	1	0
Nerve Pain [description not available]	0	5.01	3	1
Ache [description not available]	0	5.8	4	2
Dysesthesia [description not available]	0	2.01	1	0
Complications, Infectious Pregnancy [description not available]	0	2.01	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	5.01	3	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	5.8	4	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	4.27	4	1
Reticulum Cell-Like Sarcoma, Yoshida [description not available]	0	2.01	1	0
Recrudescence [description not available]	0	7.27	9	3
Acute Retinal Necrosis [description not available]	0	7.4	2	0
Bone Cancer [description not available]	0	2.01	1	0
Osteogenic Sarcoma [description not available]	0	2.91	4	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.01	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.91	4	0
Leucocythaemia [description not available]	0	5.38	5	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	5.38	5	1
Acute Disease Disease having a short and relatively severe course.	0	5.69	4	1
Chronic Illness [description not available]	0	4.84	4	2
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	4.84	4	2
Cancer of Colon [description not available]	0	2.91	4	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.91	4	0
Microbial Superinvasion [description not available]	0	2.03	1	0
Acantholytic Dyskeratotic Epidermal Nevi [description not available]	0	2.03	1	0
Infections, Poxviridae [description not available]	0	2.03	1	0
Diseases of Immune System [description not available]	0	1.96	1	0
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	0	1.96	1	0
Hepatitis B Virus Infection [description not available]	0	5.14	2	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	0	5.14	2	1
Glandular Fever [description not available]	0	2.88	1	0
Lymphocytopenia [description not available]	0	2.88	1	0
Alveolitis, Fibrosing [description not available]	0	2.88	1	0
Infectious Mononucleosis A common, acute infection usually caused by the Epstein-Barr virus (HERPESVIRUS 4, HUMAN). There is an increase in mononuclear white blood cells and other atypical lymphocytes, generalized lymphadenopathy, splenomegaly, and occasionally hepatomegaly with hepatitis.	0	2.88	1	0
Lymphopenia Reduction in the number of lymphocytes.	0	2.88	1	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	0	2.88	1	0
Infections, Respiratory [description not available]	0	2.88	1	0
Fibroma, Shope [description not available]	0	3.28	2	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	2.88	1	0
Carcinoma, Anaplastic [description not available]	0	1.96	1	0
Cancer of Mouth [description not available]	0	1.96	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	1.96	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	1.96	1	0
Keratitis Inflammation of the cornea.	0	4.45	5	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	0	3.98	5	0
Grippe [description not available]	0	1.96	1	0
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	0	1.96	1	0
Hypogammaglobulinemia [description not available]	0	1.96	1	0
Agammaglobulinemia An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.	0	1.96	1	0
Aujeszky Disease [description not available]	0	2.66	3	0
Brain Inflammation [description not available]	0	5.87	9	1
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	0	5.87	9	1
Bovine Diseases [description not available]	0	1.96	1	0
Furrow Keratitis [description not available]	0	7.05	24	4
African Lymphoma [description not available]	0	1.96	1	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	0	1.96	1	0
Penile Diseases Pathological processes involving the PENIS or its component tissues.	0	1.96	1	0
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	0	3.76	2	1
Corneal Diseases Diseases of the cornea.	0	2.36	2	0
Pyrexia [description not available]	0	1.96	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	0	1.96	1	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	0	1.96	1	0
Iritis Inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris.	0	2.37	2	0
Cold Sore [description not available]	0	3.58	3	0
Infectious Skin Diseases [description not available]	0	1.96	1	0
Herpes Labialis Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.)	0	3.58	3	0
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	0	1.96	1	0
Keratitis, Ulcerative [description not available]	0	4.83	4	2
Injuries, Eye [description not available]	0	1.96	1	0
Corneal Ulcer Loss of epithelial tissue from the surface of the cornea due to progressive erosion and necrosis of the tissue; usually caused by bacterial, fungal, or viral infection.	0	4.83	4	2
Eye Injuries Damage or trauma inflicted to the eye by external means. The concept includes both surface injuries and intraocular injuries.	0	1.96	1	0
Glioblastoma with Sarcomatous Component [description not available]	0	2.39	2	0
Benign Neoplasms, Brain [description not available]	0	1.98	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	1.98	1	0
Gliosarcoma Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)	0	2.39	2	0
Glial Cell Tumors [description not available]	0	2.4	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.4	2	0
B16 Melanoma [description not available]	0	1.98	1	0
Hepatitis, Animal INFLAMMATION of the LIVER in non-human animals.	0	1.99	1	0
Inflammatory Pseudotumor [description not available]	0	1.99	1	0
Microglossia [description not available]	0	1.99	1	0
AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.	0	1.99	1	0
Granuloma, Plasma Cell A slow-growing benign pseudotumor in which plasma cells greatly outnumber the inflammatory cells.	0	1.99	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	0	2	1	0
Verruca [description not available]	0	2	1	0
Warts Benign epidermal proliferations or tumors; some are viral in origin.	0	2	1	0
Pink Eye [description not available]	0	1.97	1	0
Dermatoses [description not available]	0	2.37	2	0
Episcleritis [description not available]	0	1.97	1	0
Conjunctivitis INFLAMMATION of the CONJUNCTIVA.	0	1.97	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.37	2	0
Scleritis Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.	0	1.97	1	0
Cancer of Liver [description not available]	0	1.97	1	0
Cancer of Lung [description not available]	0	1.97	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	1.97	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	1.97	1	0
Experimental Hepatoma [description not available]	0	1.97	1	0
Brain Swelling [description not available]	0	2.88	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	0	2.88	1	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	0	1.97	1	0
Leukemia, Lymphocytic [description not available]	0	1.97	1	0
Gingivostomatitis, Herpetic [description not available]	0	2.37	2	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	0	1.97	1	0
Stomatitis, Herpetic Stomatitis caused by Herpesvirus hominis. It usually occurs as acute herpetic stomatitis (or gingivostomatitis), an oral manifestation of primary herpes simplex seen primarily in children and adolescents.	0	2.37	2	0
Itching [description not available]	0	1.96	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	0	1.96	1	0
Antibody Deficiency Syndrome [description not available]	0	3.35	1	1
Gestational Pemphigoid [description not available]	0	3.35	1	1
Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.	0	3.35	1	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.88	1	0
Fish Diseases Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).	0	1.97	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	1.97	1	0
Experimental Leukemia [description not available]	0	1.97	1	0
Germinoblastoma [description not available]	0	3.35	1	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	3.35	1	1
Plasma Cell Tumor [description not available]	0	1.96	1	0
Plasmacytoma Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.	0	1.96	1	0

brivudine

Description

Cross-References

Synonyms (82)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Biological Processes (6)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (1277)

Research

Studies (499)

Market Indicators

Research Demand Index: 38.06

Study Types

Clinical Trials (1)

Trial Overview

brivudine

Description

Cross-References

Synonyms (82)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Biological Processes (6)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (1277)

Research

Studies (499)

Market Indicators

Research Demand Index: 38.06

Study Types

Clinical Trials (1)

Trial Overview

Related Drugs (1,321)

Related Conditions (234)